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ABSTRACT 
 
Development of Nano-scale and Biomimetic Surfaces  
for Biomedical Applications.  (August 2005) 
James Edward Henry, B.S.; M.S., University of Arkansas 
Co-Chairs of Advisory Committee: Dr. Theresa Good 
     Dr. Daniel Shantz 
 
The work described in this dissertation details the development of a biomimetic 
materials for use in sensors and therapeutics, based on new advances in material science.  
The sensors developed herein target neurodegenerative diseases.  Two of the diseases, 
the transmissible spongiform encephalopathies (TSEs) and Alzheimer’s disease (AD), 
are diseases associated with the abnormal folding of a protein, thus detecting the disease 
is dependent upon developing structure specific sensor technologies.  Both sensors 
developed in this work take advantage of the unique optical properties associated with 
nanoscale metal particles, however they use different types of spectroscopies for optical 
detection of the presence of the disease associated abnormal protein, and different types 
of recognition elements that bring the disease associated proteins close to the nanoscale 
metal particles.  In the case of TSEs, the recognition element was a commercially 
available antibody.  In the case of AD, the recognition element was a molecular scale 
self-assembled surface.  A therapeutic for AD was developed based on the molecular 
scale materials developed for the AD biosensor.  Mathematical models were developed 
 iv
that facilitated the rational design of the biosensors described in this work that could also 
be used in future biosensor development. 
 v
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CHAPTER I 
 
INTRODUCTION 
 
In the past decade, advances in material science have led to the development of 
new materials that can be used in biotechnology and medicine as part of sensors and 
therapeutics.  Two areas in particular have had breakthroughs in technology, the 
development of nanoscale materials and the development of self-assembled molecular 
surfaces. 
Nanoparticles are any particle-like structure that is on the nanometer scale.  Some 
of these nanoparticles are formed from a metal or metal complex.  The small size of 
these particles causes them to exhibit unique properties.  Currently, the unique 
electrochemical properties of nanoparticles are exploited for use in catalysis and gas 
sensing [1, 2, 3].  Nanoparticles are also used in magnetic resonance imaging (MRI) and 
electron microscopy imaging [4, 5, 6].  Furthermore, there has been some work 
expanding into the area of using nanoparticles as carriers for use in protein introduction 
in vitro, to protect the protein from degradation [7].  However, the most interesting 
property of nanoparticles in how they apply to this work is how the electromagnetic field 
of these particles, when in the presence of a light source, can greatly alter the optical 
properties of objects close to the nanoparticle (a few nanometers away). 
 
 
This thesis follows the style of the Journal of Analytical Biochemistry. 
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To fully take advantage of the unique optical properties of metal nanoparticles in 
sensor development, we had to create a way to selectively bind the target analyte to the 
nanoparticles to achieve the appropriate distance.  Monoclonal antibodies are the most 
commonly used material which binds with high affinity and specificity to a protein or 
biological material, however, they are of relatively large molecular dimensions, on the 
order of 8 nm, which limits their utility in nanoparticle based sensor applications.  It is 
this requirement for small molecular size of a recognition or binding element that led us 
to the development of self-assembled molecular surfaces with small molecular size but 
high affinity for the target analyte that are described in this work. 
Self-assembled molecular surfaces are any materials that naturally align 
themselves into a well-ordered, structured surface.  This behavior is described by such 
phenomena as the formation of self-assembled monolayers by alkanethiols and 
polymers, the formation of micelles by phospholipids, or the assembly of peptides into 
tertiary structures.  Self-assembling peptides and polymers have been used as adhesion 
substrates in tissue engineering [8, 9, 10].  Additionally, thiol-based monolayers are used 
to form coatings to prevent corrosion and oxidation of metals and other surfaces [11, 
12].  Finally, self-assembled materials have been used as substrates for micropatterning 
and sensing platforms, generally used in surface plasmon resonance [13-23]. 
While the advances in the material sciences alone are important, to design and 
build them into useful devices, such as biosensors or therapeutics, requires an 
interdisciplinary understanding of several scientific fields.  The work described in this 
dissertation details the development of a biomimetic materials for use in sensors and 
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therapeutics, based on these new advances in material science.  The sensors developed 
herein target neurodegenerative diseases.  Two of the diseases, the transmissible 
spongiform encephalopathies (TSEs) and Alzheimer’s disease (AD), are diseases 
associated with the abnormal folding of a protein, thus detecting the disease is dependent 
upon developing structure specific sensor technologies.  Both sensors developed in this 
work take advantage of the unique optical properties associated with nanoscale metal 
particles, however they use different types of spectroscopies for optical detection of the 
presence of the disease associated abnormal protein, and different types of recognition 
elements that bring the disease associated proteins close to the nanoscale metal particles.  
In the case of TSEs, the recognition element was a commercially available antibody.  In 
the case of AD, the recognition element was a molecular scale self-assembled surface.  
A therapeutic for AD was developed based on the molecular scale materials developed 
for the AD biosensor.  Mathematical models were developed that facilitated the rational 
design of the biosensors described in this work that could also be used in future 
biosensor development. 
 4
CHAPTER II 
 
LITERATURE REVIEW 
 
Introduction 
There have been several recent advances in material science that have impacted 
biotechnology and bioengineering.  Among these advancements, two standout as 
influential and are relevant for the work discussed here:  nanoparticles and self-
assembled molecular surfaces.  These advances in material science have led to advances 
in biotechnology and medicine such as more rapid sequencing of the genome, new 
technologies for tissue engineering, and development of biomimetic surfaces. 
 
Nanoparticles 
Nanoparticle development 
Nanoparticle based sensor systems have been in development since about the 
early 1980’s [24, 25].  The development started with the reports that certain metals and 
semiconductor colloidal suspensions showed unusual optical properties [26].  However, 
this phenomenon seemed to be most pronounced with particles on the nanometer scale 
[24].  As an extension of this phenomenon, semiconductor nanocrystals showed the 
ability to produce fluorescence that was up 20 times more intense and 100 times more 
stable than conventional fluorophores [25].  It was also found that nanoscale metal 
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particles of certain noble metals could dramatically alter the natural spectra of nearby 
molecules [26]. 
 The principles that lead to the interesting optical effects associated with 
nanoparticles arise from the physical characteristics of the nanoparticles.  The changes in 
optical properties relate back to the plasmons and resonant frequencies of the particles. 
Surface enhanced fluorescence occurs when the excitation of the fluorescent compound 
is coincident to the surface plasmon frequency of the particle. The nanoparticle 
“focuses” the excitation source that is incident to the particle surface.  When the 
fluorophore is in close proximity, the nanoparticle can transfer the absorbed excitation 
energy to the fluorophore, in turn increasing the excitation energy delivered to the 
fluorophore and increasing the fluorescence.  This creates the effect of increasing the 
quantum efficiency (ratio of energy absorbed to energy emitted) of the fluorophore, 
leading to an increased signal [27-29].  Most spectroscopic techniques using 
fluorescence modification in the presence of nanoparticles involve the use of molecular 
beacons for the detection of DNA and RNA [30-34].  However, this shift in optical 
properties can be tied to other techniques. 
Surface enhanced Raman spectroscopy (SERS) relies on gold or silver 
nanoparticles for their ability to increase Raman spectra of target analytes in a solution 
or on a surface.  This technique relies on the same physical properties discussed earlier, 
with the exception that instead of increasing fluorescence, the particles increase the 
Raman scatter of the target.  However, SERS generally relies on nonspecific aggregation 
of these nanoparticles to the target of interest.  We propose that by attaching a 
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recognition molecule to these SERS substrates, we can produce a specific SERS sensor 
[35 – 40].   
 
Surface plasmon resonance (SPR) 
Surface plasmons are charge density waves propagating along the interface of a 
metal and a dielectric media [41].  For metals to exhibit strong surface plasmon 
resonance, the free electrons associated with the metal must be mobile (have low 
electrical resistance).  This property makes silver and gold the best options for SPR.  
While gold features a good chemical stability, silver provides sharp SPR resonance 
peaks.  Kretchmann’s method is the most predominant method used in SPR.  This 
method uses the phenomenon of total reflection [42].  The method relies on the partial 
penetration of light as it passes through the interface of two media of different optical 
densities.  The partial penetration of light (one wavelength in depth) creates an 
evanescent wave that excites molecules near the material media interface.  In SPR, the 
evanescent wave couples with the free oscillating electrons (plasmons) of a thin metal 
film placed at the interface.  Adsorption and desorption from the metal film creates shifts 
in the resonance angle of the plasmon.  It is this angle shift that is detected [42, 43]. 
 
Surface modified fluorescence 
 Surface modified fluorescence relies on the interaction of a fluorophore or other 
fluorescent compound with some surface or particle with electrons available for 
interaction.  This behavior is related to the surface plasmon of the material and the 
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resonant frequency of the modifier [44].  Förster resonance energy transfer (FRET) is a 
form of surface-modified fluorescence that relies on the photonless transfer of energy 
from one fluorophore to another (when the donor emission overlaps the receiver 
excitation) [44].  For both systems, there is a very strong dependence on distance.   
A variety of assays that exploit changes in fluorescence in the vicinity of a 
nanosurface have been developed recently.  Most of these have been used in the form of 
molecular beacons.  Recent work indicates the use of this technique for the detection of 
prostate-specific antigens [26] and blood-glucose levels [45].  This broad application of 
the technology allows it to be an excellent cross-material sensing platform. 
 
Surface enhanced Raman spectroscopy (SERS) 
Surface enhanced Raman spectroscopy (SERS) is a Raman spectroscopic 
technique that provides greatly enhanced Raman signal from analyte molecules that have 
been adsorbed onto certain specially prepared metal surfaces. Increases in the intensity 
can be as high as 108 and 1014 for some systems [46, 47].  Raman is ineffective for 
analyte studies at low concentration due to weak vibrational modes being undetectable 
over background signal.  SERS selectivity of surface signal results from the presence of 
surface enhancement mechanisms only at the surface. Thus, the surface signal 
overwhelms the bulk signal. The majority of this enhancement is attributed to 
electromagnetic effects (EME) at the metaled surface [48].  The structural and molecular 
identification power of Raman combined with the EME makes SERS useful for the 
detection of trace molecules [46].  SERS is observed primarily for analytes adsorbed 
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onto coinage (Au, Ag, Cu) or alkali (Li, Na, K) metal surfaces, with the excitation 
wavelength near or in the visible region [49].  However, many metals would be capable 
of exhibiting SERS.    Metals such as Pd or Pt exhibit enhancements of about 102-103 for 
excitation in the near ultraviolet [47].  The importance of SERS is that the surface 
selectivity and sensitivity extends Raman utility to a wide variety of interfacial systems 
previously inaccessible to Raman due to low surface sensitivity.  In addition to the 
positives previously discussed, SERS can be conducted under ambient conditions and 
has a broad wavenumber range [50].  Unlike other vibrational spectroscopies, SERS can 
be performed in the presence of water, as Raman is most sensitive to non-polar 
molecules.  SERS shows higher enhancement on roughened metal surfaces [51].  The 
features are generally less than 100nm (which is quite small compared to the wavelength 
of the excitation source) [47, 52].  The small size of the particles allows the excitation of 
the metal particle’s surface plasmon to be localized. The resultant electromagnetic 
energy density on the particle is the source of the EME, the primary contributor to 
SERS.  It is SERS and surface-modified fluorescence that we use in the development of 
the sensors described in this work. 
 
Self-assembled molecular surfaces 
Self-assembled molecular surfaces can be formed from a number of materials.  
These include the use of biological materials such as phospholipids and peptides.  More 
expansively, the use of alkanethiols and polymers on different surfaces has been 
investigated extensively.  Uses for these materials are numerous.   
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As discussed previously, self-assembling peptides and polymers have been used 
as adhesion substrates in tissue engineering [8 - 10].  Self-assembled materials have been 
used as substrates for corrosion prevention, micropatterning and sensing platforms.  The 
sensing platforms are generally used in surface plasmon resonance and focus on the 
assembly of the monolayer itself and not what is happening external to the monolayer 
[11 - 23].  Relying on works performed by Laibinis and others, we intend to look at how 
to take advantage of the monolayer for assembly of and recognition surface substrate [53 
- 55].  Some work has been done in this field, generally in the area of tissue engineering. 
Self-assembled materials have been used to guide cell growth and adhesion in 
tissue engineering [56 - 59].  These self-assembled materials (particularly peptides) have 
been analyzed for cytocompatability [8].  Expanding on this, work applying these self-
assembled materials for direct tissue replacement is underway involving both hard and 
soft tissue replacement [60]. 
Some of the most interesting and applicable work is in area of microarrays for 
biosensing.  Little work has been done in the area, with most of it involving the use of 
immobilized antibodies for use microarrays [61].  However, this technique does not take 
advantage of properties of the self-assembling materials.  The assembled material is 
simply a tethering molecule.  We propose and prove that by using self-assembled 
monolayers we can block nonspecific binding, create surface flexibility, minimize 
distance, and mimic biological surfaces [62 - 64].  Many bio micro electric mechanical 
systems (bioMEMS) use the self-assembled materials structurally; however, this 
neglects the fact that self-assembled materials (particularly self-assembled monolayers 
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(SAMs)) can serve not only structural, but functional purposes as well.  SAMs can allow 
for close assembly to a substrate for sensing purposes (i.e. SERS) where simply tethering 
a biological receptor or antibody would prove fruitless (due to distance constraints and 
the large size of receptors and antibodies).  It is this area of self-assembly that we exploit 
in this work.   
 
Rationale for sensor modalities 
Sensors in food and pharmaceutical industry 
Food-borne illnesses are an increasing threat in today’s society.  The food 
pathogen testing/biosensor market is expected to grow to approximately $200 million in 
2005, with common pathogens such as E. coli and Salmonella and conventional 
microbiological assays and DNA/PCR based methods still important [65].  
Compounding the situation with food-borne illnesses is the immergence of new threats 
(i.e. Bovine Spongiform Encephalopathy) requiring the development of practical and 
robust detection methods [66, 67].   
 
Bovine spongiform encephalopathy (BSE) 
No disease has captured public awareness or scientific concern quite like bovine 
spongiform encephalopathy or as it is more commonly known, mad cow disease.  Public 
anxiety grew as more and more information came forward about this illness.  Officials in 
the United Kingdom made public on March 20, 1996, a possible link between BSE and 
what was believed to be a new, lethal human illness called new variant Creutzfeldt-
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Jakob disease (vCJD).  In the statement, the officials stated that 10 people in the UK had 
been diagnosed with vCJD in the previous 14 months [66].  Similarly, around the same 
time, a case of vCJD was reported in France [67].  By October, 1997, there were 10 
additional cases in the UK [66].  Upon further investigation, it was proposed that the 
onset of vCJD was caused by the ingestion of BSE contaminated meat.  Based on reports 
from the Center for Disease Control, as of the end of 2003, there have been a total of 158 
cases of vCJD worldwide (147 in the UK) [68]. 
With no current known treatment for vCJD, the only way to control the spread of 
this disease is to eliminate the consumption or use of BSE contaminated materials in 
food products or pharmaceuticals.  While measures are in place to prevent the spread of 
BSE to countries outside of the UK, and to eliminate infected cattle, no system is fool-
proof as evidenced by the recent report of BSE infected cattle in Alberta, Canada.  In 
order to prevent the spread of vCJD in humans, sensitive and robust sensor technologies 
are needed to detect the transmissible agent in BSE. 
Bovine Spongiform Encephalopathy (BSE) and new variant Creutzfeldt-Jacobs 
Disease (vCJD) are both transmissible spongiform encephalopathies (TSE).  They are 
fatal, neurodegenerative diseases that can affect both animals and humans.  The diseases 
are characterized by protein aggregate deposits in the brains of the infected organism.  
The most distinguishing characteristic of both of these conditions is that they are 
transmitted via infectious proteins, or prion, rather than bacteria or viruses [69].  These 
infectious proteins are resistant to heat, ultraviolet radiation, ionizing radiation, and most 
normal disinfectants (i.e. formaldehyde and gluteraldehyde) [70]. 
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Prions (PrP) are defined as proteinaceous infectious particles that lack nucleic 
acid. The normal cellular form of the prion is called PrPC and is readily digested by 
proteases.  The pathogenic form of the prion is called PrPSC and is partially resistant to 
proteases [71].  PrPC is found in healthy neuronal tissue and is encoded by a single copy 
host gene [70].  It appears to be involved in dendritic extension, antibody-antigen 
trapping [72], and possibly in calcium control [73].  PrPC has a molecular weight of 
35kDa and is a membrane bound protein whose secondary structure consists of 
approximately 42% α−helical and 3% β−sheet.  PrPSC, however, has a molecular weight 
of only 27-30kDa and has a secondary structure that is about 30% α−helical and 43% 
β−sheet [74].  It is this increased β−sheet structure of the PrPSC that leads to aggregation 
and protease resistance.  When PrPSC comes into contact with PrPC, the infectious 
protein causes the normal prion to refold itself into the infectious form.  This is how the 
protein propagates. 
New variant Creutzfeldt-Jacobs Disease (vCJD) occurs in people ages 19-39 
years of age.  This disease exhibits a number of psychiatric and/or sensory symptoms.  
Theses symptoms include, but are not limited to:  fatigue, disordered sleep, decreased 
appetite, memory loss, loss of vision, and loss of various mental and physical abilities 
[75].  The symptoms continue to worsen until eventual death (a length of approximately 
14 months from onset).  vCJD is often misdiagnosed as Alzheimer’s disease (however 
because of the early onset age, this is less common now) [76].  The only definitive way 
to diagnose vCJD is by histological examination of the brain of the infected person [70].  
Upon examination, the brain exhibits deposition numerous PrP amyloid plaques in 
 13
multiple cortical and subcortical regions [77].  This has been shown to lead to diffuse 
neuronal degeneration and glial cell proliferation, giving rise to the typical spongiform 
(or sponge-like) appearance of infected brain upon autopsy [76]. 
 
Current detection methods – hamster model 
 Bioassays are the traditional assays for prion protein detection since the 
discovery of transmissible spongiform encephalopathies.   This style of assay involves 
injecting material into the brain of some host animal and watching for symptoms of 
prion infection.  After some set period of time that is defined by the incubation period of 
the host animal (the shortest being 60 days is the case of the golden Syrian hamster), the 
host animal is killed and its brain is examined for signs of prion infection (i.e. protein 
plaque formation).  The first useful form of these bioassays was the transmission of 
scrapie from mouse to golden Syrian hamsters, hence the name the “Hamster Model” 
[78]. 
 
Current detection methods – immunoassay approaches 
While there are several different variations of immunoassays that have been 
developed, they all generally rely on the same principles.  These assays use either 
monoclonal or polyclonal antibodies to detect the presence of prion proteins.  In the 
general ELISA form of immunoassays, the sample is immobilized in a well on a 
microplate.  The well is washed carefully and then treated with an antibody to the target 
prion (primary antibody).  The well is then washed again and treated with an antibody 
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against the primary antibody (secondary antibody).  The secondary antibody is normally 
labeled with an enzyme to some substrate that will give a colorimetric response 
depending upon the concentration of the secondary antibody.  The enzyme normally 
used in horseradish peroxidase [79]. 
The second form of immunoassays used for prion detection rely on a standard 
Western blot technique do detect the infectious prion.  This process is performed by first 
treating the samples with proteinase K, and then performing a western blot on the 
digested sample.  The monoclonal antibody used in this technique will only bind to the 
undigested fragments that showed some resistance to protease K.  These prion pieces are 
from the infectious form of the prion [80]. 
While both these techniques have shown acceptable detection limits (down to 
approximately 5 pg / ml or 185 fM), they have certain shortcomings [80].  Both 
techniques take moderately long periods of time to obtain results (2 to 4 days).  Also, 
these techniques take rather substantial levels of specialized training.  Finally, these 
techniques, due to the response being visual, are semiquantitative.  This leads to the need 
for a simple, robust, rapid, and sensitive method for the detection of prion proteins in 
foodstuffs [69]. 
In addition to foodstuff concerns, we must also become more aware of the 
expanding use of biological products in the pharmaceutical industry.  Recombinant 
protein products are becoming much more prominent in today’s pharmaceutical 
manufacturing procedures (such as cell culture based pharmaceuticals and tissue 
engineering materials).  With this expansion comes the need for even greater safety 
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measures in the event of cross-species contamination from opportunistic viral agents.  
This leaves a substantially large opportunity for biosensor development. 
 
Sensors in the medical industry 
There is also a growing need for detection methods to be used in biomedical 
applications (i.e. diagnostics).  With the advent of molecular medicine, advances in 
disease treatment are being made faster than advances in diagnosis [81].  For some 
diseases such as Alzheimer’s disease (AD), when definitive diagnosis can only be made 
post mortem, the need for new diagnostic technology is apparent.  Further compounding 
this need for an AD diagnostic tool are the costs facing the U.S. and other countries for 
AD patient care. 
 
Alzheimer’s disease 
 Alzheimer’s disease is a neurodegenerative disease that is characterized the by 
the aggregation and deposition of β-amyloid (Aβ) in the brain.  It is the leading cause of 
neurodegradation in the United States.  As of 2003, there were 4.5 million cases in the 
United States.  This number is expected to grow to greater than 14 million by 2050 [81]. 
 The large number of AD patients in the United States leads to medical costs of an 
estimated $100 billion per year, with $61 million incurred by U.S. businesses.  Most of 
this cost can be attributed to long-term care of patients that can no longer take care of 
themselves [81]. 
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 Progression of the disease starts with the aggregation of Aβ in the entorhinal 
cortex of the brain, the memory processing center.  This aggregation is marked by the 
formation of senile or neuronal plaques between neurons and neurofibrillary tangles 
inside neurons.  The disease progresses to the hippocampus (responsible for complex 
memory), and finally the neocortex (top, responsible for sorting stimuli and orchestrating 
behavior), with both senile plaques and neurofibrillary tangles accompanying the 
neurodegeneration.  In addition to the plaques and tangles, there is noted mass loss and 
rutting of the brain.  This progression eventually leads to death (on average 9 years after 
the onset of symptoms [82].  AD can only be diagnosed definitely by post-mortem 
analysis of the brain [81].   
Aβ is the primary protein component of senile plaques.  Aβ is produced from the 
proteolytic processing of amyloid precursor protein (APP).  This processing is 
performed by two proteolytic enzymes, β-secretase and γ-secretase.  Upon cleavage, a 
peptide sequence ranging form 39 to 43 amino acids long (~4100 Da) is created.  In 
healthy adults, this protein is cleared easily.  This clearance is made possible by cleavage 
of the protein by α-secretase.  However, in AD brains, the protein aggregates (forms β-
sheet structures).  These structures progress on to protofibrils (fibril precursors) and 
eventually fibrils (long, thin protein microtubules).  All known genetic mutations that 
lead to familiar AD are associated with the processing and aggregation of Aβ [81].   
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Aβ detection techniques 
 Diagnosis of Alzheimer’s disease (AD) is done by clinical analysis of symptoms 
(dementia, loss of memory, etc.).  Unfortunately, this form of diagnosis is not absolute, 
since any neurological disease that causes the same symptoms could be misdiagnosed as 
AD.  This means that the only way definitively diagnose AD is by post-mortem analysis 
of the victim’s brain.  During the autopsy, certain hallmarks are analyzed to verify the 
pre-mortem diagnosis (amyloid fibrils, senile plaques, neurofibrillary tangles, loss of 
brain mass, severe rutting and degradation). 
 There is currently a major push in academic research to develop other methods 
for Aβ detection.  One area of interest is using amyloid-reactive dyes that to bind to the 
fibrils and plaques [83].  This technique would be used to image the brain.  While 
excellent for imaging, this technique creates two major problems.  First, the issue of 
crossing the blood-brain barrier has to be overcome.  Second, these dyes are not specific 
to Aβ fibrils.  This means that any amyloid based neurological disease would be labeled 
by the dye.  It’s important to be able to distinguish one disease from another to institute 
the proper treatment.  This is especially important as new advances in AD treatment such 
as vaccines and Aβ aggregation inhibitors are on the horizon [84, 85]. 
 Other than dyes, most techniques revolve around standard laboratory analysis 
techniques.  One method is via immunoprecipitation-HPLC-Mass spectroscopy [86].  
This method is not used for in-patient detection and relies on standard ELISA 
technology.  However, the immunoprecipitation step creates a dilemma.  It’s known that 
Aβ changes structures based on the ionic strength, acidity, temperature, etc. of the 
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environment in which it is placed.  This means that the sample that is being analyzed at 
the end of the procedure is not the same sample that was pulled from the patient.  
Furthermore, this technique requires a substantial amount of time and training (up to a 
week for sample preparation and analysis).  Since this is just an extension of ELISA, the 
same argument can be made for any immunoassay that is used. 
 Other methods that are suggested use standard MRI to detect both mass loss in 
the brain and the formation of amyloid plaques [87, 88].  However, MRI systems can 
only detect unusually large plaque formations (therefore only able to detect very 
advanced cases).  Additionally, while plaques are a hallmark of the disease, the 
mechanism for neuronal degradation from Aβ is not completely understood.  Current 
beliefs indicate that the toxic species is not the plaques, but some precursor (which will 
have already been present for a substantial length of time prior to plaque formation) [89, 
90].  Using PET scans has also been suggested, but this requires the use of radioactive 
substrates for imaging and can only tell a loss of metabolic activity in the brain (so it can 
only detect once the brain is wasting) [91].  By the time either of these techniques is 
useful, treating the patient is purely academic, with little hope of major improvement.   
 With the difficulties of detecting Aβ directly, many people are looking for 
markers that are related to Aβ formation.  The markers include amyloid precursor 
protein, presenilin-1 [92], mitochondrial damage [93], tau protein, ptau protein [94], and 
insulin degrading enzyme (IDE) [95].  These markers can all be found in cerebrospinal 
fluid, with the exception of mitochondrial damage.  The fact that these markers do not 
require brain tissue samples for detection indicates a legitimate potential for the 
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detection of these markers to be used in a diagnostic procedure for AD.  However, the 
relationship between these markers and the development of AD has not characterized to 
the point necessary to rely on these markers alone.  Conversely, the link between Aβ 
fibrils and AD has been substantially studied and is widely accepted [96 - 100].  It is for 
this reason we feel that a sensor or assay based on detection of structure specific forms 
of Aβ is superior to what else is being developed.  A SERS based assay that was specific 
for Aβ would provide both the concentration and structure information thought needed 
for diagnosis of AD and monitoring of disease progression. 
 
AD therapeutic techniques 
Most clinically used treatments for AD that have been developed to date have 
nothing to do with actually treating the cause of the disease, or even preventing or 
slowing further neurodegeneration.  They focus on treating the symptoms to improve the 
quality of life.  One example is the use of acetyl cholinesterase inhibitors to increase the 
amount of acetylcholine in patients with AD (acetylcholine is responsible for 
transmitting the signals involved in memory and cognition).  While this helps with 
memory, the neuronal degradation continues.  This is why it is important to treat the 
underlying cause of the disease. 
Most researchers believe that Aβ is the (or one of the) causative agents in AD.  It 
has been shown to be neurotoxic both in vivo and in vitro when aggregated [96].  
Overexpression of APP with mutations that lead to Aβ production results in the 
development of AD like symptoms in transgenic mice [89].  Vaccines that sequester 
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aggregated Aβ appear to reduce AD like symptoms in transgenic models of the disease 
[84].    
Agents which either sequester Aβ or interfere with Aβ interaction/binding to 
cells have been sought after as a means to reduce the pathological effects of Aβ  [97, 101 
- 104].  We believe that the same biomimetic materials developed that provide molecular 
scale high affinity interaction with Aβ for sensing might also be developed into a 
therapeutic which interferes with Aβ-cell interactions to prevent Aβ induced 
neurodegeneration. 
 
Sensor design 
 Sensors are an important combination of two fields.  The first is the development 
of some recognition unit toward an analyte of interest, be it a protein, peptide, cell, 
compound or single element (such as in oxygen sensors).  The second step is developing 
some sort of signaling technique.  These range from optical based (absorbance, 
fluorescence, etc.) to electrical transduction as is found in enzymatic sensors.  The 
challenge lies in how to link these two in way that can be used as a sensor.  It is this 
challenge that requires the incorporation of multiple disciplines and ideas. 
 
Recognition methods for sensors 
With any sensor, it is required to have high specificity and affinity.  ELISA-like 
assays use antibodies (which have very high specificity and affinity) as recognition 
molecules.  Applying the use of antibodies, we have been able to develop a solution-
 21
based sensor for the detection of Bovine Spongiform Encephalopathy (BSE) prions.  
This sensor shows lower recognition limits on the order of 1nM (approximately equal to 
the equilibrium binding coefficient for the antibody) with high specificity. 
In parallel, the recent development of mini-mAbs (bacterially produced light 
chain antibodies of monoclonal antibodies) greatly expands the possibilities of these 
sensors [105].  With these mini-mAbs showing much smaller molecular weights than 
antibody fragments (25-30kDa compared to 50kDa), there use in highly dependant 
distance-based sensors (FRET, SERS, surface-modified fluorescence based) is attractive.  
For distance-based sensors, the measured variable varies by one over distance to the 
sixth.  Therefore, every bit of distance that can be eliminated helps. 
Another option for recognition molecules includes the use of cell surface 
receptors to develop sensors for serum-based measurements.  Elevated levels of serum 
analytes have been linked to several diseases (soluble IL2 receptor for hepatitis C or 
glucose levels in diabeties) [106, 107].  When the use of these surface receptors is not 
possible, it is important to be able to develop something that can be used in its place, a 
biomimetic structure.  We were able to do just that when constructing sialic acid 
modified dendrimers to mimic cell surface gangliosides for both sensing Aβ and 
preventing Aβ toxicity.  Using an expansion of this principle, it would be possible to 
immobilize the cell membranes from a desired cell to a sensor surface to keep intact an 
entire receptor complex and not just a single receptor.   
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Recognition molecules 
 While the options for recognition molecules are substantial, there has been little 
done to expand into new recognition detection areas.  Most work being done in sensor 
recognition is in the area of either immuno-based recognition, enzymatic recognition, or 
cell receptor-based recognition. 
 Immuno-assays range in use from standard ELISA techniques to immobilized 
antibodies for use in SPR.  While antibodies show excellent affinity values (109 M-1), 
they have limitations in that their size (~150 kDA) can cause interference in size-
dependant assays.  Furthermore, if the target analyte is a protein, then IR, Raman, and 
rayleigh scatter can have overlapping (interfering) signatures [108 - 112]. 
 Enzymatic recognition has many similar characteristics to immunological 
recognition, but with smaller protein size.  Enzymes also have the bonus that they can 
perform auto-amplification (as in colorimetric assays and electrical based recognition).  
However, when destruction of the desired analyte is not acceptable, this leads to 
enzymatic sensing being a hindrance.  Additionally, enzymes have substantially lower 
binding coefficients than antibodies (106 M-1) [113 - 118]. 
 Cell receptors have the similar characteristics to antibodies.  While surface 
receptors produce extremely high affinity (107 - 1010 M-1), harvesting these receptors can 
be extremely difficult [119 - 121].  In addition, because cell surface receptors are 
typically found in the context of the cell membrane, the solubility and/or stability of cell 
receptors in solution is sometimes problematic. 
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Electrical-based detection methods 
 Biosensors based on electrical transducers are the most commonly used for 
clinical analyses and the most frequently cited in the literature.  Amperometry is the 
electrochemical technique usually applied in commercially available biosensors.  
Amperometry is an electrochemical technique taking advantage of the fact that certain 
chemical species are oxidized or reduced (redox reactions) at metal electrodes when 
exposed to a constant potential.  Related to amperometry is coulometry.  Coulometry is 
an electrochemical technique where the amount of charge passing between two 
electrodes is measured.  The amount of charge passing between the electrodes is 
proportional to oxidation or reduction of an electroactive substance at one of the 
electrodes [45, 122 - 124].  The technique has been applied to glucose detection in cell 
cultures [125]. 
Potentiometry is the measurement of the potential difference between two 
electrodes when the current is zero. The two electrodes are known as the indicator and 
reference electrodes.  The indicator electrode develops a variable potential depending on 
the activity or concentration of a specific analyte in solution.  The difference in potential 
between the reference and indicator electrode is related to concentration of the analyte. 
Ion-selective electrode (ISE) a potentiometric technique routinely used in clinical 
chemistry for the detection of electrolytes.  A change in solution conductivity has also 
been used in enzyme-based biosensors.  When an alternating potential is applied 
between two inert electrodes, the conductance of the solution is measured.  Some 
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enzyme reactions, producing a change in the ionic strength of the sample, may be 
monitored by conductometric devices [126 - 128]. 
Piezoelectric detection is a technique that relies on a change in the oscillatory 
properties of a polymer or crystal substrate in the presence of a target analyte.  This 
system relies on the change in frequency of oscillation of the polymer/crystal due to 
increased mass upon absorption of some target analyte.  This increased mass leads to a 
decrease in the oscillation rate of the polymer which can be measured.  This technique 
has great promise due to its low detection limits (picograms), but is limited by 
immobilization and processing issues. [129 - 132]  In particular, the mass of the 
absorbed analyte must be significant with respect to the mass of the recognition unit, 
such that the change in mass is detectable above system noise. 
   
Optical-based detection methods 
To expand this idea into enzyme detection systems, enzyme based sensors 
(amperometric) have been explored extensively.  However, little work has been done in 
the area of SERS, FRET, and surface-modified fluorescence based enzyme sensors.  
Much of the chemistries involved in immobilizing enzymes for amperometric detection 
could be used in the construction of surface based detection systems like the one listed 
above.  This would allow for redundant sensor systems for verification. 
Finally, if the target is an organism (or virus), modifying these systems for DNA 
detection is simple.  Many of the techniques required for this modification are based on 
the work that has been developed in the area of molecular beacons (fluorescence based 
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DNA detection system).   Many of these systems could be altered to be used for positive 
or negative detection (increase or decrease in signal, respectively).  The choice of which 
method to use would be dictated by the system being developed. 
As for the bio-optical sensors side of the system, this is where the incorporation 
of ideas from several disciplines is important.  Knowing our limitations, we rely heavily 
on the expertise of Dr. Gerard Coté.  His extensive work in bio-optics has allowed us to 
incorporate some unusual and creative ideas into the design of the recognition substrates 
[133, 134]. 
 
Modeling in sensor design 
 Sensor design is challenging in many aspects.  When designing a sensing system, 
it is important to understand the characteristics of the system thoroughly.  Things to 
consider are the response of the sensor in the presence of analyte, the binding affinity of 
the sensing molecule to the target of interest, the specificity of the sensor, and the 
influence of background on detection capabilities.  To experimentally determine these 
characteristics can be extremely time consuming and expensive.  This is where the use of 
modeling is crucial. 
 Most modeling today is done post-experimentation.  Modeling is used as an 
empirical way to describe the results achieved through experimentation.  While it is 
useful to be able to understand the trends of the data after collection, this completely 
neglects another aspect of modeling, intelligent experimental design.  Often modeling 
can allow you to eliminate conditions or sensor designs that will not function in an 
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acceptable manor in the conditions available.  It is this trend in current sensor design that 
we took advantage of in this project [135 - 140]. 
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CHAPTER III 
 
MODELING FOR INTELLIGENT SENSOR DESIGN 
 
Introduction 
In any developmental research, trial-and-error approaches prove often to be both 
time consuming and financial restrictive.  However, without large amounts of a priori 
information, a certain amount of guesswork is required.  Making these attempts 
“educated guesses” is what’s important.  By performing modeling of the sensor system 
before hand, one can quickly rule out sensor schemes that are far from optimal and focus 
on the more viable candidates. 
 Currently, we’re looking at detection techniques for amyloid proteins.  These 
proteins are the causative agents and/or toxic species of interest in Mad Cow disease 
(prion), Creutzfeldt-Jakob disease (prion), Alzheimer’s (Aβ), Huntington’s disease 
(huntingtin), and several others.  The diseases are characterized by the 
neurodegeneration due to the aggregation and formation of amyloid fibrils by the species 
of interest (as indicated in parenthesis).  The requirements of the sensor are that it be 
sensitive to levels found in vivo, selective for amyloid proteins, and provide structure 
information for the analyte of interest. 
 While the molecules we wish to detect and the sensor application define the 
physical constraints of the biosensors we will develop, the models that we describe to 
evaluate their feasibility are broadly applicable.  In each model developed, we assume 
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that the analyte of interest binds to a recognition molecule with a given binding affinity, 
and that the binding of the analyte to the recognition molecule results in a detectable 
change in signal.  Our particular biosensor applications are based on surface modified 
spectroscopic techniques, thus the signal is assumed to be either an emission or 
absorption intensity.  The signal is either generated by binding the analyte directly or via 
the displacement of a competing molecule.  Equilibrium and dynamic cases of these 
types of sensors are explored. 
 
Materials and methods 
Materials 
 All models were derived based on standard chemical and biochemical kinetic 
principles and equations.  The models were solved under desired conditions using 
MATLAB v. 7.0.1 (The MathWorks, Inc. Natick, MA).  The resulting data were 
compiled and plotted using Microsoft (Seattle, WA) Excel 2002. 
 
Competitive (indirect) equilibrium model 
 With a competitive sensing system, there are three major components.  These 
components are the recognition unit (R), the first target (signal unit (S)), and the second 
target (analyte (A)).  For a standard equilibrium competition system, the recognition unit 
and signal unit are combined and allowed to come to equilibrium.  Upon equilibration, 
the sample of interest is added.  If the target is present, the system will come to new 
equilibrium conditions with the analyte (in turn displacing a fraction of the signal unit).  
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This displacement will lead to a new equilibrium condition between the recognition unit 
and the signal unit.  The result will be a change in the signal intensity from the original 
equilibrium situation.  It is the change that is measured to determine the analyte 
concentration.  Figure 3.1 demonstrates this system (schematic of competitive sensor). 
 
 
Fig 3.1 Schematic of competitive equilibrium sensor.  The recognition unit (R) binds to the signal unit (S).  This 
leads to some baseline signal.  Upon introduction of the target analyte (A), A displaces some of the S bound to 
R, creating a new signal 
 
 
 
 Based on this model, there are several variable of interest to consider.  Aside 
from concentrations of signal unit, recognition unit, and analyte (which can be easily 
controlled), there are three major variables of interest.  The first is the equilibrium 
binding conditions between the signal unit and recognition unit.  This is governed by the 
equilibrium binding coefficient for these two units (Ks-r).  The second variable is the 
equilibrium binding between the analyte and recognition unit (and in turn the 
equilibrium binding coefficient for these two (Ka-r).  The final variable is how the signal 
intensity of the signal unit changes upon binding with the recognition unit (Fb). 
 Taking into account just the kinetics of the system, we arrive at a system of 
equations as follows: 
SRkRSk
dt
SRd
rrsfrs ***
)(
,, −− −=   (3.1) 
R S S + R A R S + A + 
ks-r,f 
ks-r,r 
ka-r,f 
ka-r,r 
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 Where: SR = Concentration of recognition unit / signal unit complex 
  AR = Concentration of analyte / signal unit complex 
  S = Concentration of signal unit 
  A = Concentration of analyte 
  R = Concentration of signal unit 
  ks-r,f = Reaction constant for S / R association 
  ks-r,r = Reaction constant for S / R dissociation 
  ka-r,f = Reaction constant for A / R association 
  ka-r,r = Reaction constant for A / R dissociation 
  Ks-r = Equilibrium coefficient for formation of the SR complex 
  Ka-r = Equilibrium coefficient for formation of the AR complex 
The independent forward and reverse rates dictate how quickly equilibrium is achieved. 
However, these rates do not affect the actual concentrations of the system at equilibrium. 
 While kinetics dictate the system, the signal determines usability.  Looking at 
signal intensity as a function of different of concentration of different species (R and SR 
are the only species of interest when determining signal; the other species do not 
contribute to signal), we arrive at the following equation: 
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RISRII freeboundtotal ** +=   (3.5) 
 Where: Itotal = Total signal intensity of the system 
  Ibound = Signal intensity of bound signal unit 
  Ifree = Signal intensity of free signal unit 
Normalizing the system by the intensity of the free signal unit (Ifree) we arrive at the final 
form of the equation: 
  RSRFIR
I
I
SR
I
I
I
I
bnormtotal
free
free
free
bound
free
total +=⇒+= *** ,  (3.6) 
 Where: Itotal,norm = Normalized total signal intensity of the system 
  Fb = Fractional change in signal upon binding 
The system of equations (3.1 – 3.4 and 3.6) were solved simultaneously using MATLAB 
v. 7.0.1 (The MathWorks, Inc. Natick, MA).  Normalized signal intensity as a function 
of analyte concentrations were evaluated at equilibrium (the time derivative of all 
concentrations were equal to zero).  The sensitivity of normalized intensity to model 
parameters (Ka-r, Ks-r, and initial concentrations of R, and S) was investigated 
 
Competitive (indirect) dynamic model 
 This competitive sensing field is similar to the one described in the previous 
section except for the caveat the equilibrium with the final sample cannot be achieved 
due to the degradation of  the target to some final product.  An example of such a system 
is an enzyme based detection of some target analyte.  Figure 3.2 depicts such a system.  
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Fig 3.2 Schematic of competitive dynamic sensor (enzymatic).  The recognition unit (R) binds to the signal unit 
(S).  This leads to some baseline signal.  Upon introduction of the target analyte (A), A displaces some of the S 
bound to R, creating a new signal.  An additional complication occurs due to the regeneration of R by the 
conversion of A to product (P). 
 
 
The equations governing the system are as follows:  
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 Where: P = Concentration of product formed from analyte degradation 
  kc = Reaction constant for degradation of analyte to product 
R S S + R A R S + A + 
ks-r,f 
ks-r,r 
ka-r,f 
ka-r,r 
R S + + P 
kc 
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Again, normalizing the system by the intensity of the free signal unit (Ifree) we arrive at 
the final form of the equation: 
 
dt
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dt
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I
dt
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I
I
dt
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b
normtotal
free
free
free
boundtotal +=⇒+= )(**)(* ,  (3.14) 
By monitoring the rate of change in fluorescence intensity, we can determine the 
concentration of target analyte in the sample.  Equations (3.7 – 3.11 and 3.14) were 
solved simultaneously using MATLAB 7.0 and the rate of change in fluorescence as a 
function of analyte concentration was determined at different model parameter values. 
 
Direct equilibrium model 
 Direct sensors rely on a change in some measurable variable upon the interaction 
of the analyte of interest with the recognition molecule in the system.  In the system we 
describe, the sensor relies on a change in the optical properties of the system upon 
binding of analyte.  More specifically, the model is based on the surface-enhanced 
Raman spectroscopy (SERS).  In SERS, the target analyte exhibits an increase in 
spectroscopic signal upon interacting with some enhancing substrate (i.e. gold).  The 
enhancement factor can be as high as 1012.  A schematic of the biosensor system is seen 
in Figure 3.3. 
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Fig 3.3 Schematic of direct equilibrium sensor.  The recognition unit (R) is immobilized to a signaling substrate.  
Upon introduction of the target analyte (A), A binds to R, creating a signal. 
 
 
 The equations governing this system are very similar to those above.  However, 
the system is simpler since it doesn’t rely on a secondary molecule for the detection.  
The governing equations are as follows: 
ARkRAk
dt
ARd
rrafra ***
)(
,, −− −=   (3.15) 
  ARFFAISignal distenhfree *** +=   (3.16) 
 Where: Signal = Spectroscopic signal 
  Fenh = Enhancement factor upon binding 
  Fdist = Distance factor for analyte to enhancer distance 
The enhancement factor upon binding is a function of electromagnetic properties of the 
enhancing surface, wavelength of light used to excite the surface, other physical 
properties of the system.  The distance factor for analyte to enhancer distance is a 
function of the thickness of the enhancing surface and the dimensions of the recognition 
molecule given by the function shown in Equation 3.17. 
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 Where: ro = Radius of curvature of enhancement substrate 
d = Distance from analyte to enhancing surface, typically of the 
dimensions of the recognition molecule. 
 
Results and discussion 
 The models developed were analyzed based on the variables of interest for the 
different systems.  For both the competitive equilibrium sensor and the competitive 
dynamic sensor, the values of Ro, So, Ks-r, and Ka-r were varied to determine the effect of 
those variable on the sensor behavior.  Comparatively, for the direct equilibrium sensor, 
Ro, Ka-r, enhancement factor, and the ratio of distance to diameter were varied. 
 
Competitive equilibrium model – effects of varying Ks-r 
 The equilibrium binding constant (Ks-r) represents the ratio of R-S complex to 
unbound R and S.  Increasing the value of Ks-r increases the amount of R-S complex, 
with the converse also being true.  Figure 3.4 shows the effect of varying Ks-r on the 
response of the sensor. 
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Fig 3.4   Equilibrium competitive sensing system response to changes in Ks-r.  Values of Ks-r ranging from 106 to 
1011 M-1 (decreasing as you move down the graph).  Ka-r = 108 M-1 , R0 = S0 = 10-8 M 
 
 
 As can be seen from the figure, as Ks-r increases, the linear response region of the 
sensor expands in both the active range of substrate concentrations and in the magnitude 
of the fluorescence intensity change that occurs.  However, increasing Ks-r shifts the 
lower limit of the linear region to higher values of substrate.  Therefore, maximizing Ks-r 
does not necessarily lead to optimized biosensor performance.  The value of Ks-r to use is 
dependant upon the substrate region of interest and the sensitivity of the equipment 
being used. 
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Competitive equilibrium model – effects of varying Ka-r 
 Much as Ks-r represents the ratio of R-S complex  to free R and S, Ka-r represents 
the ratio of R-A complex to R and A.  Again, increasing Ka-r increases the amount of R-
A complex.  Figure 3.5 shows the effect of varying Ka-r on the response of the sensor.  
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Fig 3.5  Equilibrium competitive sensing system response to changes in Ka-r.  Values of Ka-r ranging from 106 to 
1011 M-1 (increasing as you move down the graph).  Ks-r = 108 M-1 , R0 = S0 = 10-8 M 
 
 
 From Figure 3.5, we see that increasing Ka-r decreases the lower limit of the 
linear response region of the sensor.  However, increasing Ka-r narrows the linear region.  
Again, maximizing the value of Ka-r will not necessarily produce the optimum sensor 
performance.  As with Ks-r, the desired value of equilibrium binding constant for the 
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analyte to the recognition element is function of the desired sensor range for the 
application.   
 
Competitive equilibrium model – effects of varying S0 
 The initial amount of signaling unit (S0), also has direct consequences on 
equilibrium concentrations of free and bound analyte and signal molecule, thus will 
affect the performance and sensitivity of the biosensor.  Figure 3.6 shows this 
relationship. 
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Fig 3.6  Equilibrium competitive sensing system response to changes in S0.  Values of S0 ranging from 10-6 to 
10-10  M (increasing as you move down the graph).  Ka-r = Ks-r = 108 M-1 , R0 = 10-8 M 
 
 
S0 
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 As is apparent from the figure, increasing S0 reduces the amount of signal 
possible from the sensor, as the excess free signaling unit both shifts the concentration at 
which the analyte of interest can displace the decoy to higher concentrations and leads to 
greater background signal such that the enhancement of signal caused by binding of the 
signaling molecule to thee recognition molecule is obscured.  However, increasing 
concentrations of S0 also expands the range of concentrations of analyte detectable in the 
linear region of the sensor.   
 
Competitive equilibrium model – effects of varying R0 
 The effect of R0 on equilibrium is similar to the effect of S0.  Greater 
concentrations of R0 leads to lower concentrations of free S in system at equilibrium and 
a greater shift of the fluorescence intensity from basal value.  However, more R0 in the 
system results in R being available to bind A without displacing S, which decreases the 
effectiveness of the sensor.  Figure 3.7 demonstrates this effect. 
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Fig 3.7  Equilibrium competitive sensing system response to changes in R0.  Values of R0 ranging from 10-6 to 
10-10  M (decreasing as you move down the graph).  Ka-r = Ks-r = 108 M-1 , R0 = 10-8 M 
 
 
Summary of competitive equilibrium model results 
 In general, the lower limit of detection for the sensor is governed by Ka-r, with 
the limit of detection of analyte approaching the inverse of the value of Ka-r.  However, 
to achieve those detection limits, values of Ks-r, R0, and S0 must be matched to Ka-r.  If 
Ks-r is within an order of magnitude of Ka-r, then the detection limits of the sensor remain 
approximately the inverse of Ka-r, with larger Ks-r’s resulting in greater signal to noise 
and somewhat larger range of concentrations of analyte leading to linear sensor response.  
For lowest limits of detection, both R0 and S0 should be within an order of magnitude of 
the inverse of Ka-r, with deviations from these values leading either to a loss in 
Decreasing R0 
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sensitivity or loss in signal to noise.  Experimental verification of these findings are seen 
in Chapter IV. 
 
Competitive dynamic model 
 Unlike the competitive equilibrium sensor, in the competitive dynamic sensor, 
while the same signal generation mechanism is used (surface modified fluorescence in 
this example), the analyte of interest is degraded by the recognition element.  Therefore, 
fluorescence intensity changes with time in the sensor, and this rate of change in 
fluorescence intensity can be used to infer analyte concentrations. 
 
 Competitive dynamic model– effects of varying Ks-r 
 As seen in Figure 3.8, an increase in Ks-r leads to a decrease in the rate of change 
in signal intensity, dI/dt, (due to the increased binding affinity of the signal unit for the 
recognition molecule).  The decrease in dI/dt would result in a decrease in signal to noise, 
experimentally. Conversely, as Ks-r increases, the lower limit of detection decreases.  As 
with the equilibrium sensor, and optimum value of Ks-r exists which maximizes signal to 
noise while minimizing the concentration at which analyte is detectable. 
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Fig 3.8  Dynamic competitive sensing system response to changes in Ks-r.  Values of Ks-r ranging from 104 to 
109 M-1 (increasing as you move down the graph).  Ka-r = 107 M-1 , R0 = S0 = 10-8 M 
 
 
Competitive dynamic model – effects of varying Ka-r 
 Within the range of parameters explored, it appears that the major effect of 
varying Ka-r is to increase signal to noise (dI/dt) as the value of Ka-r increases, with 
possibly a modest effect on the upper limits of detection of the system (Figure 3.9).  Ka-r 
appears to have much less effect on system sensitivity and limits of detection in the 
dynamic sensor than in the equilibrium sensor. 
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Fig 3.9  Dynamic competitive sensing system response to changes in Ka-r.  Values of Ka-r ranging from 104 to 
109 M-1 (decreasing as you move down the graph).  Ks-r = 107 M-1 , R0 = S0 = 10-8 M 
 
 
Competitive dynamic model – effects of varying S0 
 Varying the amount of decoy available varies the intrinsic fluorescence of the 
system.  Greater concentration of decoy indicates greater fluorescence.  This allows for 
easier detection of signal, but makes the rate of fluorescence change a much smaller 
fraction of the total signal.  Figure 3.10 shows this effect. 
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Fig 3.10  Dynamic competitive sensing system response to changes in S0.  Values of S0 ranging from 10-r to 
10-12 M (increasing as you move down the graph).  Ka-r = Ks-r = 107 M-1 , R0 = 10-8 M 
 
 
 Figure 3.10 demonstrates how decreasing the decoy concentration leads to 
greater values for dI/dt.  Additionally, decreasing the decoy concentration gives better 
lower detection limits.  As previously mentioned, the caveat is that as decoy 
concentration decreases, so does total signal, placing the burden of limitations on the 
equipment being used. 
 
Competitive dynamic model – effect of varying R0 
 As discussed in the equilibrium model, increasing R0 increases the amount of 
bound decoy and free recognition unit.  This has the possible positive effect of 
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increasing the total fluorescence of the system, but with the possible negative attribute 
that the free recognition unit will decrease the sensitivity of the sensor.  Figure 3.11 
emphasizes these possible effects. 
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Fig 3.11  Dynamic competitive sensing system response to changes in R0.  Values of R0 ranging from 10-4 to 
10-12 M (decreasing as you move down the graph).  Ka-r = Ks-r = 107 M-1 , S0 = 10-8 M 
 
 
 From the figure we can see that decreasing the initial concentration of 
recognition unit improves the lower detection limits of the system.  However, decreasing 
R0 also decreases the total signal available for analysis.  This creates the same problem 
that the lower limits of R0 are governed by the equipment available. 
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Summary of competitive dynamic model 
 For a given value of Ks-r, you are limited to using concentrations of R0 greater 
than or equal to the inverse of Ks-r.  This is caused by the drastic shift of equilibrium 
toward dissociation, due to R values less than the limits just set.  Additionally, the same 
limitation hold true for the concentration of S (for the same reasons).  Since equilibrium 
limitations still apply, the limits of detection are limited by the value for Ka-r.  The 
inverse of this value also dictates R0 in addition to A0 concentrations that may be used or 
detected, respectively.  Since there are major economic limitations that are placed on the 
system by the cost of gold substrate, we are required to work at exceptionally low 
volumes (<20µL) to achieve the necessary concentration.  This is created by the fact that 
most enzymes operate with moderately low values of Ks-r (106 – 107 M-1).  These 
limitations are demonstrated in Chapter IV. 
 
Direct equilibrium model - effect of varying R0 
 Unlike the two previous models described, with a direct sensor, signal is 
generated by binding of the analyte of interest directly to the recognition molecule on the 
surface.  Since the concentration of recognition molecule on the surface, R0, is directly 
related to the amount of total possible bound analyte, model results suggest, as expected, 
that total signal intensity, signal to noise, and range of detectable concentrations would 
be greatest when the highest concentrations of recognition unit possible were bound to 
the surface (Figure 3.12). 
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Fig 3.12  Equilibrium direct sensing system response to changes in R0.  Values of R0 ranging from 10-2 to 
10-10 M (decreasing as you move down the graph, solid lines).  Signal from the free decoy represented by 
the dashed line.  Ka-r = 106 M-1, Enfac = 106, Dist/Dia = 3.33. 
 
 
 As described early, the system is more effective (more signal) with increasing 
values of R0.  However, there is one more interesting artifact.  As R0 increases, the upper 
detection limits of the system increase.  This further supports the idea that the maximum 
concentration of recognition unit should be used in the sensor. 
 
Direct equilibrium model – effect of varying enhancement factor 
 With the same predictability of varying R0, increasing the enhancement factor 
(Enfac, the increase in signal of the analyte upon binding to the surface relative to that 
free in solution) increases the effectiveness of the sensor.  This is obvious from the fact 
 48
that increasing Enfac directly increases the bound signal without influencing the kinetics 
of the system.  Figure 3.13 exemplifies this effect. 
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Fig 3.13  Equilibrium direct sensing system response to changes in enhancement factor (Enfac).  Values of 
Enfac ranging from 106 to 1012 M (decreasing as you move down the graph, solid lines).  Signal from the free 
decoy represented by the dashed line.  Ka-r = 106 M-1, R0 = 10-10 M, Dist/Dia = 0. 
 
 
Direct equilibrium model – effect of varying distance/diameter ratio 
 As the distance/diameter ratio (Dist/Dia) decreases, which physically implies that 
the recognition unit becomes smaller and the analyte comes closer to the enhancing 
surface, it is expected that the bound signal in the system will increase.   For the 
purposes of this paper, a third order decay in signal as distance increased was assumed, 
based on theoretical estimates of the decay of the electromagnetic field [46, 47] and 
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experimental measurements with different surfaces (Chapter VI).  Figure 3.14 
demonstrates the distance effects. 
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Fig 3.14  Equilibrium direct sensing system response to changes in ratio of distance from surface to 
diameter of curvature (Dist/Dia).  Values of Dist/Dia ranging from 0 to 3.33 (increasing as you move 
down the graph, solid lines).  Signal from the free decoy represented by the dashed line.  Ka-r = 106 M-1, 
Enfac = 106, R0 = 10-10 M. 
 
Direct equilibrium model – effect of varying Ka-r 
 Varying Ka-r directly affects the equilibrium conditions in the system in the same 
way as discussed in the competitive equilibrium model.  Therefore, it would stand to 
reason that by increasing the value of Ka-r, the amount of bound substrate would increase.  
This will lead to increased signal and easier detection, as illustrated in Figure 3.15.   
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Fig 3.15  Equilibrium direct sensing system response to changes in Ka-r.  Values of Ka-r ranging from 106 to 
1011 M-1 (decreasing as you move down the graph, solid lines).  Signal from the free decoy represented by the 
dashed line.  R0 = 10-10 M, Enfac = 106, Dist/Dia = 0. 
 
 
 While the increase in signal is apparent from the figure, there is another 
interesting artifact.  As Ka-r increases, the upper detection limit decreases because the 
surface saturates.   
 
Summary of direct equilibrium sensor  
 In general, the direct sensing platform is much simpler than the competitive 
platforms, but somewhat more difficult experimentally to realize.  Success depends on 
high surface coverage of the recognition unit, a physically small recognition unit (such 
that the distance from the analyte to the surface is low), and a high binding affinity of the 
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recognition unit for the analyte.  Antibodies bind with high specificity and reasonably 
high binding affinity (109 to 1012 M-1), but are molecularly rather large (4-5 nm in 
diameter).  The large size both decreases the distance of the analyte for the surface and 
decreases possible surface coverage of the recognition unit. 
 We show, with some novel molecular surfaces, that surface coverage at picomole 
levels are possible (near 10-8M for R0), with binding affinities in the range of 108 M-1, 
and at distances near 10 nm from the surface (Dist/Dia=0.067).  Our collaborators have 
generated surfaces with enhancement factors near 106 or greater.  Thus, with instrument 
sensitivity optimized (high power input, high sensitivity detector), analyte at 
concentrations below 10 nM should be detectable.  Higher concentrations of analyte, up 
to near 10 µM, should be distinguishable from signal arising from analyte free in 
solution, but signal will not increase with increasing concentration as the sensor surface 
would be saturated.  The feasibility of engineering the direct sensor, as described, is 
detailed in Chapter VI. 
 
Conclusions 
Competitive equilibrium model 
 While the trends discussed give an idea of how the system depends on each of 
these variables, the true determination of what Ka-r, Ks-r, R0, and S0 to use greatly depend 
on the range of concentrations of substrate for which detection is desired. However, it 
does appear that matching R0 and S0 concentrations seems to give the best response with 
the least loss of signal.  Furthermore, it appears that the limiting components of the 
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system will probably be the equipment being used for detection and the binding affinity 
of the recognition molecule for both analyte and signal molecule. 
 
Competitive dynamic model 
 The results of this model are significantly easier to discuss.  As is the case for all 
the variables R0, and S0, lower is better.  However, since decreasing R0 and S0 seems to 
fight the trends of each (it is not the lower value but the change in the ratio), it would be 
most beneficial to, again, match the concentrations to one another.  Conversely, 
maximizing Ka-r and Ks-r seems to be the most beneficial.  Limitations on the possible 
performance of the sensor are the binding affinities obtainable for the recognition 
molecule, the limits of equipment detection (which are limited both by power input into 
the sample and detector efficiency), and the cost constraints associated with putting 
enhancing particles (gold for example) on the recognition element. 
 
Direct equilibrium model 
 For this system, one should maximize R0 and Enfac while minimizing Dist/Dia.  
This will give the highest bound signal available.  As for Ka-r, it is important that the 
value of Ka-r matches the concentration range of interest (since increasing Ka-r decreases 
the upper detection limits, but decreasing Ka-r decreases total signal). 
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Summary 
 Keeping all of these factors in mind when designing a sensor system (regardless 
of style) can help create a much more efficient design and understanding of the system.  
Furthermore, by using models for “intelligent design”, one can fine tune the system to 
better match the capabilities and limitations of the equipment available, the biology or 
chemistry of the recognition units available, and the optical of the surface modifying 
metal particles used in biosensor development.  Furthermore, incorporating models 
along with experimentation, you can decrease the number of experiments by “testing” 
some parameters with simulation, reject certain designs because the models show they 
are not feasible, and speed up optimization process associated with biosensor 
development. 
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CHAPTER IV 
 
DEVELOPMENT OF A NANOPARTICLE-BASED SURFACE-MODIFIED 
FLUORESCENCE ASSAY FOR THE DETECTION OF PRION PROTEINS* 
 
Overview 
A nanoparticle-based immunoassay for the detection of recombinant bovine 
prion protein (PrP) was developed as a step in the development of screening tools for the 
prevention of the spread of transmissible spongiform encephalopathies. The assay is 
based on the competitive binding between PrP and a peptide–fluorophore to a 
nanoparticle-labeled antibody which is specific for a conserved prion sequence. The 
fluorophore, when bound to the antibody, is subject to surfaced-modified fluorescence, 
enabling detection of changes in the concentration of bound fluorophore in the presence 
of prion protein. Important factors considered during the development of the assay were 
ease of use, robustness, and detection level. The effects of pH and nanoparticle 
conjugation chemistry on surface-modified fluorescence observed in the assay were 
explored. Effects of concentrations of antibody and fluorophore on reproducibility and 
detection limits were examined. At present, the detection limits of the system are 
approximately equal to the antibody–peptide fluorophore equilibrium dissociation  
 
*Reprinted from the Journal of Analytical Biochemistry, 334, James Henry et al., 
“Development of nanoparticle-based surface-modified fluorescence assay for the 
detection of prion proteins,” 1-8, Copyright 2004, with permission from Elsevier.  
doi:10.1016/j.ab.2004.07.008   
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constant, which is near one nanomolar concentration. Improved assay performance could 
be obtained by optimization of the nanoparticle surface resonance effects. The simplicity 
of the assay and ease of use may make the type of assay described in this report 
attractive for screening purposes in the food industry. 
 
Introduction 
Prion proteins (PrPs) are thought to be the causative agent in transmissible 
spongiform encephalopathies (TSEs), a group of fatal neurodegenerative diseases that 
include chronic wasting disease and bovine spongiform encephalopathy (BSE) in 
nonhuman animals and Creudzfeld Jakob disease in humans [80]. The diseases are 
highly contagious in certain species, with transmission from nonhuman animals to 
humans thought to be possible, at least for BSE [80]. 
 Until methods of treatment or prevention of the diseases have been established, 
the best hope of preventing the spread of TSEs is through surveillance of animals and 
animal products including foods and pharmaceutical materials. Current screening 
methods involve the use of immunological assays such as ELISAs and Western blots 
with high sensitivity (down to the picomolar range or below), but these require 
considerable time and skill [80]. The other major screening method for the detection of 
infectious prions is the ‘‘Hamster Model’’ [78], which examines the ability of a sample 
to transmit infection to a golden hamster. This method is the only assay capable of 
definitively determining whether a sample is capable of transmitting disease; however, 
the incubation period for the hamster screening method is approximately 60 days, 
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prohibitively long for the screening of foodstuffs and the detection limits are uncertain. 
Simple, robust, rapid, and sensitive methods for the detection of prion proteins are 
needed for use in the food and pharmaceutical industries. 
In this paper, the development of a simple nanoparticle-based surface-modified 
fluorescence assay for the detection of prions is described. The assay developed is based 
on phenomena associated with the high number of surface electrons associated with 
metal nanosurfaces [141]. A variety of assays that exploit changes in optical properties 
in the vicinity of a nanosurface have been developed recently [142], including surface-
plasmon-resonance-based assays [143] and surface-enhanced resonance Raman assays 
[144]. These assays have been used in the detection of proteins including the estrogen 
receptor alpha [145], human serum albumin [146], and wheat germ agglutinin and 
epidermal growth factor [147]. Use of surface-modified fluorescence has been reported 
recently for the detection of prostate-specific antigens [148]. 
A variety of analytical techniques have been developed which exploit changes in 
fluorescence properties of a molecule in different environments, whether those changes 
be quenching [149], Förster resonance energy transfer [150], or surface-modified 
fluorescence in which the energy absorbed by the nanoparticle or nanosurface either 
quenches or enhances the fluorescence of fluorophore, depending upon the distance 
between the excited surface and the fluorophore [151]. In this work, an assay utilizing 
surface-modified fluorescence for prion detection is described. The assay is based on the 
competitive binding of a fluorophore to a nanoparticle-labeled prion-specific antibody. 
As currently implemented, the assay is simple to perform, requires minimal skill, and 
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can be used to detect recombinant prion proteins down to 2 nM. With optimization, 
including steps for the discrimination between infectious and noninfectious prion, this 
assay could be used as a rapid and simple screening tool to prevent the introduction of 
TSEs into the food and pharmaceutical supply. 
 
Materials and methods 
Materials 
The fluorescent peptide fluorescein-GABA-QYQRES-COOH, referred to as 
decoy, was custom synthesized and purified by Multiple Peptide Systems (San Diego, 
CA). Peptide purity was 85% as indicated by mass spectrometry and reverse-phase 
HPLC provided by the manufacturer. The recombinant prion protein (Calbiochem, San 
Diego, CA) was a histidine-tagged protein expressed in Escherichia coli containing 
amino acids 25–244 of the bovine PrP sequence. The anti-PrP monoclonal antibody 
(derived from cell line F99/97.6.1 from VMRD, Pullman, WA) was used in sensor 
development. The antibody was specific for the sequence QYQRES, a conserved 
sequence in human, bovine, and elk PrPs. 
The 1.4-nm gold nanoparticles for labeling of the antibody at specific residues 
were purchased from Nanoprobes (Yaphank, NY). The particles had only one 
attachment site per gold cluster with the attachment site being dependant upon the type 
of gold nanoparticles used. All other chemicals, unless specifically indicated, were 
supplied by Sigma–Aldrich (St. Louis, MO). 
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Antibody purification 
The anti-PrP monoclonal antibody (MAb) was purified on an rProtein A column 
(Amersham Biosciences, Piscataway, NJ) before use. A 2.5-mL-bed-volume column was 
used to purify approximately 7 mg of antibody. The column was .rst washed with 10 
mM borate buffer, pH 8.9, with 3 M NaCl, before use. The impure MAb, diluted 1:1 in 
pH 8.9, 3 M NaCl buffer, was loaded onto the column. The column was then washed 
with 10 bed volumes of 50 mM borate buffer, pH 8.9, 3 M NaCl, followed by 10 bed 
volumes of 10 mM borate buffer, pH 8.9, 3M NaCl. Purified MAb was eluted with the 
100 mM glycine buffer, pH 3.0. MAb was detected in fractions via absorbance at 280 
nm using the Beckman DU620 spectrophotometer (Beckman Coulter, Fullerton, CA). 
Antibody was neutralized with 1/10 volume 1 M Tris buffer, pH 8, containing 0.02% 
sodium azide. Bovine serum albumin was added to the antibody to a concentration of 2 
mg/mL to improve stability during storage. 
 
Preparation of fAb fragment 
The antibody fragments (FAb) were prepared using the ImmunoPure FAb 
Preparation Kit (Pierce Biotechnology, Rockford, IL). The procedure used was provided 
by Pierce Biotechnology [152]. 
 
Nanogold attachment 
Three different gold nanoparticle attachment chemistries were used, 
monomaleimido, mono-NHS, and monoamino, to specifically attach the gold 
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nanoparticles to the anti-PrP MAb at sulfhydryl, amine, and carbohydrate residues, 
respectively. The sulfhydryl attachment chemistry was also performed using FAb 
fragments. The procedure for the attachment of the monomaleimido nanogold to both 
whole MAb and antibody fragments at reduced sulfhydryl groups was performed 
according to the IgG and FAb attachment procedures provided by Nanoprobes with the 
following modification:  80 mM dithiothreitol was used in place of 100 mM MEA as a 
disulfide bond reducing agent [153]. The procedures for the attachment of mono-NHS 
nanogold to primary amines on the anti-PrP MAb and monoamino nanogold to oxidized 
carbohydrate chains on the Fc region of the anti-PrP MAb were performed according to 
the IgG attachment procedure provided by Nanoprobes without modification [154,155]. 
Separation of labeled antibodies from unbound nanogold particles was performed 
by ultrafiltration using Millipore (Billerica, MA) Microcon 30,000 MWCO filters. Gold 
to protein mole ratios of the nanoparticle-labeled antibody or antibody fragments were 
determined by measurement of sample absorption at 280 and 420 nm. Gold to Ab (or 
FAb) mole ratios were in the range of 1.6:1 to 4.2:1, or approximately 2–4 gold particles 
per antibody molecule. Less than 1% of total gold in each sample was unbound. 
 
Sample mixing 
The samples were mixed from stock solutions of decoy, gold-labeled MAb, 
recombinant PrP, and buffer. Stock solutions of decoy and antibody were prepared in 
phosphate buffer. Stock solutions of PrP were prepared in deionized water to avoid PrP 
aggregation. The buffer used for fluorescence measurements was 0.1 M phosphate 
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buffer, pH 7, unless otherwise specifically indicated. The samples were placed in sealed 
foil pouches and mixed for times ranging from 4 to 24 h depending on the concentrations 
of the samples. Independent fluorescent measurements were taken at various times to 
ensure that mixing times were sufficient for samples to reach equilibrium. No attempt 
was made to remove unbound decoy from samples prior to fluorescence measurements. 
Measurements were recorded from equilibrium mixtures of bound and free decoy, 
antibody–gold conjugate, and prion. 
 
Sample testing 
The fluorescence of samples was measured using a fluorometer from Photon 
Technologies International (Lawrenceville, NJ) outfitted with a 25 mW argon laser from 
Spectra-Physics Lasers and Photonics (Mountain View, CA). A 500 nM long-pass filter 
was placed in the emission light path to reduce the effects of scattered excitation light. 
Samples were excited at 488 nm and the emission was scanned from 500 to 600 nm. 
Fluorescence intensity at 514 nm was recorded. Normalized fluorescence intensity, 
reported here, refers to the fluorescence intensity of the sample at 514 nm divided by the 
fluorescence intensity of the fluorescein-labeled peptide (decoy) alone at the same 
concentration and same pH condition as that of the sample. 
 
Statistical and modeling analysis 
Data are presented as the mean plus or minus the standard deviation (or standard 
error) of n independent measurements where n is 3 or greater. To determine the 
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statistical difference of two samples or a sample from a control, a Student t test was 
performed. When multiple measurements were compared, a Tukey test was used to 
determine the statistical difference in data. Unless otherwise indicated, P < 0.05 was 
used. 
To estimate the range of conditions that should be tested to optimize assay 
performance, a simple equilibrium model of antibody–decoy and antibody–prion binding 
was constructed in which it was assumed that the equilibrium binding constants to both 
decoy and prion were the same. The decoy–antibody equilibrium binding constant, 2.5 x 
109 M-1, was estimated independently [156]. The resulting set of nonlinear equations was 
then solved using Polymath or Maple to determine free and bound decoy concentrations. 
Fluorescence intensity was assumed to be a linear combination of the fluorescence 
emission of the free decoy and that of the bound decoy and was assumed to be directly 
proportional to the concentrations of fluorescing species. While linearity of fluorescence 
intensity with free decoy concentration was confirmed experimentally, other 
assumptions in model development were not tested directly. 
 
Results and discussion 
A novel assay for the detection of PrP in buffers that was rapid and simple to use 
was developed. A simple schematic of the assay can be seen in Figure 4.1. 
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Fig. 4.1. Schematic of the prion detection system. Two reactions occur in the assay 
mixture. A fluorescent peptide decoy (D) can bind to an antibody–gold conjugate (A) 
forming an antibody–decoy complex (AD) or a prion protein (P) can bind to the 
antibody–gold conjugate forming an antibody–prion complex (AP). The fluorescence 
intensity of the decoy changes when bound to the antibody–gold complex relative to that 
of the free decoy. If, when the complex forms, the fluorophore is close to the gold 
nanoparticle (approximately 10 nm or less), the fluorescence is quenched relative to that 
observed in the free decoy. If the fluorophore is at an intermediate distance from the gold 
nanoparticle when bound (approximately between 10 and 40 nm), fluorescence is 
enhanced relative to that of the free decoy. The change in fluorescence of the assay 
mixture upon addition of prion is used to indicate the prion concentration in the sample. 
 
 
While there are prion assays with high sensitivity in current use, the level of expertise 
required for these methods and the length of time required to perform such assays can be 
a major hindrance in food manufacturing and processing environments [80, 79]. The 
assay described here was based on the competitive binding of PrP and a fluorescent 
peptide or decoy to a monoclonal antibody specific for a conserved sequence in several 
PrP species including sheep, goat, cattle, mink [157], and deer [158]. The sequence is 
near the C terminus of the prion protein, which is believed to be accessible to antibodies 
on both infectious and noninfectious prions and is unlikely to be cleaved by protease 
pretreatment of the infectious protein [80]. The fluorescence of the decoy was modified 
when bound to the antibody because of the presence of a gold nanoparticle on the 
antibody. 
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Since the assay developed here is based on competitive binding, the detection 
limits of the system will be related to the relative amounts of fluorescent decoy bound to 
the antibody and free in solution and to the differences in fluorescence intensity of the 
bound and free species. The distance between the gold nanoparticles and the fluorophore 
will greatly affect the fluorescence of the bound fluorophore as at short molecular 
distances nonradiative energy transfer to the metal leads to fluorescence quenching, 
while at longer distances (generally between 10 and 45 nm) enhancement is seen as a 
result of surface resonance effects [151]. Local pH will also affect the fluorescence of 
bound and free species. In addition, concentrations of all species participating in assay 
reactions along with equilibrium constants for those reactions will determine the relative 
concentrations of bound and free species. The effects of these parameters were explored 
to elucidate the working range and detection limits of the assay developed. 
 
Structural comparison 
The first step in the assay development was to quantify the effective change in 
peptide decoy fluorescence upon binding with gold–MAb (or gold–FAb) conjugate as a 
function of location or type of gold nanoparticles attachment. Binding of gold-labeled 
antibody to fluorescent decoy did not alter the shape of the emission spectra or 
wavelength of emission maximum but simply led to changes in intensity of fluorescence. 
Results from these experiments are shown in Figure 4.2. 
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Fig. 4.2. Effect of nanoparticle attachment chemistry on surface modified fluorescence. 
The filled bars and empty bars are 200 nM antibody, 200 nM decoy, and 10 nM antibody, 
10 nM decoy, respectively. Normalized intensity is the fluorescence of the antibody 
decoy pair divided by the fluorescence intensity of the free decoy at the same 
concentration. Error bars represent the standard deviation of three or more independent 
measurements. 
 
 
As seen in the figure, fluorescence intensity of the decoy bound to the antibody relative 
to that free in solution was a strong function of the method of gold attachment. The 
sulfhydryl–FAb, amine–MAb, and carbohydrate–MAb chemistries led to a decrease in 
fluorescence, or quenching, while the sulfhydryl–MAb chemistry led to an increase in 
fluorescence, or enhancement, of the decoy when bound to antibody relative to that of 
free decoy without antibody present. Significant variability in enhancement and 
quenching observed was noted when different batches of antibody were used in 
experiments. However, for the same batch of antibody, but different conjugation 
reactions, reproducible enhancement and quenching were observed. We assumed that the 
variability in enhancement and quenching seen with different batches of antibody were 
associated with differences between batches in stability/purity of the antibody and not 
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with differences in concentration at which the reactions were carried out. One possible 
explanation for the variation in the fluorescence modification behaviors observed with 
the different chemistries is that the different attachment chemistries led to different 
molecular distances between the nanoparticle and the bound decoy (fluorophore). For 
the sulfhydryl–FAb attachment chemistry, the average molecular distance between 
nanoparticle and fluorophore may be relatively small, leading to quenching of 
fluorescence, while for the same attachment chemistry to the whole antibody, the 
average molecular distance between nanoparticle and fluorophore was greater, leading to 
a fluorescence enhancement. For the amine attachment chemistry, considerable 
heterogeneity in molecular distances would be expected because of the relatively large 
number of possible surface amines for attachment, giving rise to small changes in 
fluorescence because of averaging of both enhancement and quenching effects. Similar 
arguments could be made about molecular distances with the carbohydrate attachment 
chemistry (small molecular distances, leading to quenching). No direct measurements of 
distances between gold attachment sites and fluorophore binding sites were attempted. 
 
pH effects 
Given that fluorescein, the fluorophore attached to the decoy used in the assay, is 
known to be pH sensitive [159], we examined the role of pH on the relative 
enhancement or quenching behavior observed when the decoy was bound to the gold-
labeled MAbs prepared with the three different attachment chemistries (Figure 4.3). 
 
 66
 
Fig. 4.3. Effect of solution pH on fluorescence intensity of decoy and decoy/antibody 
pairs. The concentration of decoy was 10 nM. The concentration of antibody–gold 
conjugates was 8 nM. The following symbols were used to represent different attachment 
chemistries: ■, sulfhydryl; □, carbohydrate; ♦, free decoy; ◊, amine. Error bars represent 
the standard deviation of three or more independent measurements. 
 
The FAb–sulfhydryl attachment was eliminated as it provided no noticeable advantage 
over other available chemistries. No obvious shifts in fluorescence dependence upon pH 
with respect to control were observed with nanogold-labeled antibodies relative to that 
of the free decoy (Fig. 4.3), suggesting that the binding showed no pH dependence. For 
subsequent experiments, pH 7 was used. Since the sulfhydryl and carbohydrate 
chemistries showed the most promise, they were the only chemistries used in further 
testing. 
 
Decoy:Ab ratio 
As seen in Figure 4.4, we explored the effect of the relative ratio of decoy to 
gold-labeled antibody on normalized fluorescence intensity. We expected, based on 
stoichiometric arguments, that optimal enhancement or quenching would be observed 
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when decoy to antibody ratios were between 1:1 and 2:1. A maximum was observed for 
the sulfhydryl attachment chemistry at a decoy to antibody ratio of 1.25:1 (Fig. 4.4). 
 
 
Fig. 4.4. Effect of decoy to antibody mole ratio on normalized fluorescence intensity for 
different conjugation chemistries. The following symbols represent different attachment 
chemistries: ■,sulfhydryl; □, carbohydrate. Points labeled with like symbols are 
statistically equivalent (Tukey, P < 0.05). 
 
There were no significant changes in normalized fluorescence intensity in the range of 
ratios between 1:1 and 2:1 when the carbohydrate attachment chemistry was used. The 
1.25:1 decoy to antibody ratio was used in all subsequent experiments. 
Whether this represents the true mole ratio of decoy to antibody under conditions 
that yield maximum changes in fluorescence signal or whether the observed optimal 
ratio was due to some uncertainty in our measurements of antibody or decoy 
concentrations is not clear. However, it should be noted that these results were observed 
consistently with multiple batches of antibody–nanoparticle conjugations. 
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Detection limits 
Using the optimum decoy to antibody ratios, we then determined the minimum 
concentrations of decoy and antibody that could be used and still reveal a significant 
difference between the fluorescence intensity of decoy bound to the gold-labeled 
antibody and that of free decoy. Results from those experiments are seen in Figure 4.5. 
 
 
Fig. 4.5. Effect of decoy/antibody pair concentration on normalized fluorescence 
intensity for different attachment chemistries. The following symbols were used to 
represent different attachment chemistries: ■, sulfhydryl; □, carbohydrate. The 
normalized fluorescence intensities for sulfhydryl-labeled Ab and carbohydrate-labeled 
Ab were statistically different from the normalized control value (1.0) for concentrations 
at and above 2 and 3 nM, respectively (Student’s t test, P < 0.01). 
 
 
At concentrations below 2 nM decoy for the sulfhydryl chemistry and below 3 nM decoy 
for the carbohydrate chemistry, no differences between free and bound decoy were 
detectable (P < 0.01). The concentrations at which no statistical difference between free 
and bound decoy could be detected approaches the equilibrium dissociation constant for 
the Ab:Decoy system (approximately 4 x 10-10 M) [156]. 
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Prion displacement 
The principle of the assay under development was that of competitive binding of 
the decoy and prion to the antibody. Thus, in the absence of the prion, the decoy would 
bind to the antibody and its fluorescence would be modified by the gold nanoparticle. 
However, in the presence of the prion, the decoy would be displaced, and fluorescence 
would return to unmodified levels. A number of experiments were performed to test the 
ability of the prion to displace the decoy and whether the assay could be used to detect 
recombinant prion in the system (Figure 4.6). 
 
 
Fig. 4.6. Normalized fluorescence intensity as a function of recombinant prion 
concentration in solution. Sulfhydryl attachment chemistry is indicated with filled 
symbols. Carbohydrate attachment chemistry is indicated with open symbols. All 
measurements were performed at pH 7.0. Diamonds, 200 nM decoy, 160 nM antibody. 
All values (other than 0 nM PrP) are statistically different from the 0 nM PrP value 
(Student’s t test, P < 0.05). Squares, 5 nM decoy, 4 nM antibody. All values of 
fluorescent intensity except 20 nM PrP (carbohydrate attachment chemistry only) 
samples are statistically different from the fluorescence intensity of free decoy 
(normalized intensity of 1). All values of fluorescence intensity are statistically different 
from the 0 nM PrP values, indicating that all concentrations tested could be distinguished 
from zero prion concentration (Student’s t test, P < 0.05). Triangles, 2 and 3 nM for 
sulfhydryl and carbohydrate attachment chemistries, respectively, 1.25:1 decoy:antibody 
ratio. Fluorescence intensities of prion-containing samples are statistically different from 
that of free decoy for concentrations less than 5 nM PrP. Fluorescence intensities of 
prion-containing samples 3 nM and above can be distinguished from the fluorescence 
intensity of zero prion samples (Student’s t test, P < 0.05). 
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The first attempt was performed at high decoy and antibody concentrations (200 nM 
decoy concentration, pH 7, 1.25 decoy to antibody ratio, diamond symbol). As prion was 
added to solution, the fluorescence intensity of the decoy increased from that of the 
quenched level of decoy bound to gold-labeled antibody toward the fluorescence 
intensity of free decoy (in the absence of antibody). The normalized fluorescence of the 
200 nM prion sample was significantly different from that of the decoy–antibody 
controls (P < 0.05). However, at very high prion concentrations, 2 µM, the fluorescence 
decreased relative to that at lower prion concentrations, possibly due to prion 
aggregation in high-ionic-strength solution [160]. The histagged prion protein did not 
appear to aggregate at lower concentrations unless stored in high-ionic-strength buffers. 
Further prion displacement assays were performed at lower decoy and antibody 
concentrations to improve the limits of sensitivity of the assay. When decoy 
concentrations of 5 and 2 or 3 nM were used (keeping the decoy to antibody ratio fixed 
at 1.25 to 1), the assay could be used to distinguish 2 nM prion from zero prion in the 
sample as opposed to the 200 nM lower limit observed when 200 nM decoy was used 
(based on a Student t test with P < 0.05). The observed trend of the limits of detection of 
prion, corresponding roughly to the decoy concentration used in the assay, was expected 
based on simple equilibrium models of the reactions taking place in the assay. The 
working range of the assay was 2–10 nM (for carbohydrate chemistry) or 20 nM (for 
sulfhydryl chemistry) when 5 nM decoy was used (squares), while it was 2–5 nM when 
the lower decoy concentrations were used (triangles). 
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The equilibrium model was used to estimate normalized fluorescence intensity 
for an enhancement-based assay, analogous to the system employing sulfhydryl 
chemistry described here, as a function of concentration of prion at different 
concentrations of antibody and decoy (Figure 4.7). 
 
 
Fig. 4.7. Equilibrium model estimates of normalized fluorescence intensity as a function 
of prion concentration for an enhancement based assay. In model calculations, the 
equilibrium binding constants for both antibody to decoy and antibody to prion were 
assumed to be 2.5 x 109 M-1. The maximum possible enhancement was assumed to be 1.6 
times the fluorescence intensity of the unbound decoy. Equimolar decoy and antibody 
concentrations were assumed at 200 nM (diamonds), 10 nM (squares), 1 nM (triangles), 
and 100 pM (circles). 
 
The equilibrium models showed that the limits of detection of the system corresponded 
to the equilibrium dissociation constant for the antibody to the decoy, that the limits of 
detection for each antibody and decoy concentration corresponded approximately to the 
decoy concentration used, and that at very low antibody and decoy concentrations 
(below the dissociation constant), normalized fluorescence intensity decreased, 
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suggesting that the signal to noise ratio would also decrease. These observations are 
consistent with experimental data shown in Fig. 4.6. To reduce further the detection 
limits of the assay, the equilibrium binding coefficient would have to be increased, either 
by finding a different antibody or by altering the ionic strength and temperature at which 
the assay was performed [161, 162] or both. 
Detection was also limited by background fluorescence of free decoy or decoy 
bound to antibody, for enhancement and quenching chemistries, respectively, which 
increased the noise in the system. Improved surface-modified fluorescence effects might 
be obtained through use of silver deposition on the gold nanoparticle, which would both 
increase surface roughness and alter the absorbance of the particles such that they would 
better match the excitation source [151]. For better enhancement specifically, outside of 
better control of molecular distances and resonance effects, it would be necessary to 
change to a lower-quantum-efficiency fluorophore [151]. 
 
Conclusions 
It has been demonstrated that it is feasible to detect nanomolar concentrations of 
recombinant prion protein in a simple and reproducible assay that uses surface-modified 
fluorescence. The strengths of the method are its simplicity, ease of use, and relative 
speed which are appropriate for screening technologies for the food industry. However, 
we were not able to achieve the femtomolar detection limits of current detection methods 
(ELISAs) [79, 80]. To further increase the sensitivity of a surface-modified 
fluorescence-based system beyond the limits of the affinity of the antibody, it would be 
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necessary to create an assay that was no longer competition based. In addition, with the 
current system, the natural fluorescence of biological molecules (along with the 
scattering effects of a serum-based sample) would create significant ‘‘noise’’ in the 
output leading to a decreased sensitivity of the assay. This problem could be addressed 
by shifting to a longer-wavelength fluorophore to reduce the effects of scatter and the 
intrinsic fluorescence of biological samples. Finally, the current method as described 
would require modifications to the sample to allow for the discrimination between 
infectious and noninfectious prions. This could be accomplished by pretreating the 
samples with proteinase K or other selective proteases prior to sample analysis [163]. 
This step would, of course, increase the difficulty and time required for the assay to be 
performed. 
In summary, surface-modified fluorescence assays such as the one described here 
can be used for the detection of biologically important proteins. The method is simple 
and fast and has a sensitivity approximately equal to the antibody–antigen equilibrium 
dissociation constant. In applications where very high-affinity antibodies are available, 
where the sensitivity needs are on the order of nanomolar concentrations, or where ease 
of operation are important, assays such as the one that we have described may be 
appropriate. 
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CHAPTER V 
 
PRELIMINARY WORK TOWARDS THE DEVELOPMENT OF AN 
ORGANOPHOSPHATE ENZYMATIC SENSOR 
 
Introduction 
 The wide spread use of neurotoxic organophosphates (OP) in the environment for 
insect and pathogen control and recent threats of OP based chemical warfare agent 
involvement in ground based warfare and terrorist attacks necessitate the development of 
simple and specific methods for OP detection. Organophosphorus (OP) neurotoxins 
comprise a unique class of contaminants and chemical warfare agents (CW) that 
generally show low environmental persistence, but they have a high acute toxicity and a 
wide range of biological activities. Some members of this class are extremely toxic to 
mammals (e.g. the human oral lethal dose for paraoxon = 16 mg/kg, and VX is lethal at 
1 mg if ingested or 100 mg-min/m3 if inhaled); they are powerful inhibitors of enzymes, 
such as Acetyl- and Buturyl-Cholinesterases or Neurotoxic Esterase, which are involved 
in nerve function. Moreover, low doses, but long-term exposure of these neurotoxins 
may lead to the development of cancer, genetic diseases, and other dangerous effects. 
OP neurotoxins are capable of producing organophosphate-induced delayed 
neurotoxicity (OPIDN) in man and susceptible species. Recovery from these complex 
and poorly understood diseases is usually poor and there is no specific treatment, as 
observed for many Gulf War participants.  
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A variety of methods including gas, liquid, and thin-layer chromatography with 
mass spectrometry or other sophisticated spectroscopic detection methods have been 
used for organophosphate identification and detection.  These approaches are very 
sensitive but require expensive equipment and are not specific for organophosphates.  
Another approach has been the use of biosensors that use specific enzymes such as 
acetylcholinesterase or butyryl cholinesterase as the recognition element [164 - 166]. 
Organophosphate neurotoxins inhibit the activity of the enzymes, thus inhibition of their 
activity can be used as an indirect measure the "total anticholinesterase activity" of a 
sample (with sensitivity up to 10-10 M) but are prone to interference by a environmental 
contaminants such as heavy metals or phenols.  
 Another approach has been to use organophosphate hydrolase as the principle 
component of biosensors for the direct detection of organophosphates [167 - 169].  The 
enzymatic hydrolysis of OP neurotoxins by organophosphate hydrolase (OPH) generates 
two protons in each hydrolytic turnover through a reaction in which P-O bonds are 
cleaved.  Several strategies, potentiometric and fluorescence, have been used to detect 
the generation of protons, with sensitivity down to 1 µM [170, 171].  While sensitive, 
these sensors are very sensitive to the buffering capacity of the sample.   
 In this work, we examine the feasibility of developing a biosensor using 
organophosphate hydrolase as a recognition element, and surface modified fluorescence 
spectroscopy as a detection method for a variety of organophosphate neurotoxins.  This 
work builds on our previous success in the development of a surface modified 
fluorescence method for the detection of prions [172], preliminary work of our 
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collaborators on the development of a nanoparticle based sensor for organophosphate 
detection [173], and our modeling efforts detailed in Chapter III.   
 The system uses a fluorescent competitive inhibitor of OPH as the detection 
analyte.  By isolating the enzyme in close proximity to a fluorescence modifier (e.g. 
gold), we can alter the fluorescence intensity of the inhibitor upon it binding to OPH.  
Because the reaction is enzymatic, rate of change of fluorescence can then be used as an 
indicator of the presence of organophosphate neurotoxin.  This differs significantly than 
sensor methods that we have previously developed.  In addition, the gold-laden OPH 
will be produced either through direct gold-labeling of the enzyme, or by creating a 
gold-rich hydrogel in which the enzyme is contained.  The end goal of the work is to 
develop a detection methodology that is portable and affordable, such that communities 
can monitor their water/soil for OP pesticide contamination and/or OP chemical warfare 
agents.  
 
Materials and methods 
Materials 
 The OPH was supplied by Dr. Jim Wild from the Department of Biochemistry 
and Biophysics at Texas A&M University.  Paraoxon was purchased from Chem Service 
(West Chester, PA).  Nanogold was purchased from Nanoprobes, Inc (Yaphank, NY).  
N-dodecyl-N,N-dimethylamine N-oxide (DDAO), DDAO phosphate, and Texas Red 
were purchased from Molecular Probes (Eugene, OR).  Acryloyl polyethylene glycol N-
hydroxysuccinimide (Acryloyl-PEG-NHS) was purchased from Nektar Therapeutics 
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(Huntsville, AL).  Irgacure 2959 photoinitiator was acquired from Ciba Specialty 
Chemicals (Tarrytown, NY).   The Spectroline EN-180 Longwave UV Lamp was 
purchased from Spectronics Corporation (Westbury, NY).  Fluorescence and absorbance 
was measured using an Applied Photophysics (Leatherhead, Surrey, UK) PiStar system 
equipped with stopped-flow capability. Centrifugal filter units were purchased from 
Millipore Corporation (Billerica, MA).  All other chemicals and supplies were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
Gold labeling of OPH – all gold types 
Three different gold nanoparticle attachment chemistries were used, 
monomaleimido, mono-NHS, and monoamino, to specifically attach the gold 
nanoparticles to the organophosphate hydrolase (OPH) enzyme at sulfhydryl, amine, and 
carbohydrate residues, respectively.  The procedure for the attachment of the 
monomaleimido nanogold was performed according to the large protein attachment 
procedure provided by Nanoprobes with the following modification:  200 mM 
dithiothreitol was used in place of 100 mM MEA as a disulfide bond reducing agent 
[153].  The procedures for the attachment of sulfo-NHS nanogold to primary amines and 
monoamino nanogold to oxidized carbohydrate moieties were performed according to 
the protein and glycoprotein attachment procedure, respectively, provided by 
Nanoprobes without modification [154, 155]. 
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Determination of kinetic constants for OPH enzyme in the absence and presence of 
inhibitors DDAO phosphate and coumarin-1.  
Enzyme activity in the absence of inhibitors was determined mixing equal 
volumes of 20nM OPH in PBS (pH=7.0) and solutions of varying concentrations of 
paraoxon.  The absorbance of the mixture was measured at 340nm to monitor the 
production of p-nitrophenol (the degradation product of paraoxon by OPH) as a function 
of time.  The data were then analyzed to find initial rates of paraoxon hydrolysis as a 
function of substrate concentration. Km and kcat were then estimated by fitting initial rate 
data to a standard Michaelis –Menton kinetic expression. 
DDAO phosphate was mixed in varying concentrations ranging from 10 to 
100µM with 20nM OPH in PBS (pH=7.0).  Paraoxon stock was made by dissolving 
paraoxon in DMF to a concentration of 100 mM.  The stock was diluted in PBS to 
varying concentrations ranging from  10 to 1000µM.  DMF was added to a concentration 
of 4% (v/v).  The OPH/DDAO phosphate solution and the paraoxon solution were mixed 
in equal volumes using the stopped-flow attachment for the PiStar system.  The 
absorbance was measured at 340nm to monitor the production of p-nitrophenol  as a 
function of time.  The data were then analyzed to find initial rates of paraoxon 
hydrolysis as a function of substrate and inhibitor concentration. Km, kcat, and KI were 
then estimated by fitting initial rate data to a standard Michaelis –Menton kinetic 
expression that included competitive inhibition.  Analogous experiments were performed 
to determine an inhibition constant (KI) for OPH with coumarin 1. 
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Fabrication of hydrogel for enzyme/dye immobilization 
 Polymer precursors were made by producing a PEG-DA solution containing 
0.5% Irgacure 2959 and 10% acryloyl-PEG-NHS.  Texas Red, coumarin 1, and gold-
labeled OPH were added in varying concentrations to the polymer mixture.  From the 
resulting mixture, a 10 µL dot was applied to a thin strip of polystyrene.  The dot was 
placed under the UV curing lamp at a distance of ½ inch for 10 minutes (~260 mW/cm2). 
 
Measurement of gold-modified fluorescence of OPH-coumarin 1 system 
 The hydrogel dot was placed at a ~45o to the light path in the fluorometer.  The 
emission intensity of the coumarin 1 was monitored at 468nm while exciting at 390nm.  
Texas red was used for normalization (since the exact sample volume in the path could 
not be maintained from one slide to the next).  This was done by measuring the emission 
intensity of Texas red at 610nm while exciting at 510nm.  The value for the emission of 
coumarin 1 was then divided by the emission intensity of Texas red to compensate for 
difference in the material light paths. 
 
Results and discussion 
OPH temperature study 
 The first concern we had when working with OPH was creating the best 
environment for the sensor and the enzyme.  We knew that temperature would effect the 
system and attempted to find the ideal working temperature (with reasonable laboratory 
operating conditions being somewhere between 5oC and 25oC.  From this work, we can 
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to the conclusion that within that range, 25oC was the best conditions for operation.  This 
was due to the increased reaction rates allowing for quicker detection.  
 
OPH-DDAO phosphate inhibition study 
 In order to develop a surface modified fluorescence assay for organophosphates, 
a suitable fluorescence inhibitor must be identified.  By recommendation of Dr. Alex 
Simonian at Auburn University, we tested DDAO phosphate as an inhibiting dye for the 
sensor system.  This was performed as described previously.  Figure 5.1 shows the 
results of this study. 
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Fig 5.1.  DDAO phosphate inhibition results.  This figure shows how the enzymatic reaction curve 
varies with DDAO phosphate concentration.  The rates reported are initial rates measured within the 
first minute of reaction.  The resulting data was analyzed to find the linear region closer to time zero.  
The DDAO phosphate concentration for each curve is as follows:  ♦ - 0 µM, ■ – 4.90 µM, ▲ – 8.17 
µM, ● – 16.34 µM, ◊ - 32.68 µM, and □ – 49.02 µM. 
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 From this figure, it is apparent that the inhibition effect from DDAO phosphate is 
not competitive (as expected or desired).  With a competitive inhibitor we would expect a 
constant value for Vmax, with Km increasing with increasing inhibitor concentration.  This 
is not what is happening here.  This is further exemplified by Figure 5.2. 
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Fig 5.2. Lineweaver-Burke analysis of DDAO phosphate inhibition.  Plotting 1/V vs. 
1/[PX],  allows for the calculation of Vmax (and in turn, kcat) from the inverse of the y-
intercept and the calculation of Km by multiplying the slope by Vmax.  The DDAO phosphate 
concentration for each curve is as follows:  ♦ - 0 µM, ■ – 4.90 µM, ▲ – 8.17 µM, ● – 16.34 
µM, ◊ - 32.68 µM, and □ – 49.02 µM. 
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 Neglecting the highest DDAO phosphate concentration (there were problems with 
DDAO phosphate solubility), we can analyze the curves to obtain the values for Km and 
Vmax for each curve.  From this, we obtain the following (Table 5.1): 
 
Table 5.1.  Summary of Lineweaver-Burke analysis 
 
[PX] (µM) 
 
Vmax (M/s) 
 
Km (M) 
 
0 3.72 x 10-6 2.00 x 10-5 
4.90 3.52 x 10-6 2.10 x 10-5 
8.17 3.02 x 10-6 2.05 x 10-5 
16.34 2.75 x 10-6 2.03 x 10-5 
32.68 2.32 x 10-6 1.97 x 10-5 
 
  
 
From Table 5.1, it is apparent that Vmax is a function of DDAO phosphate concentration.  
This, however, is not true for Km, which remained constant over all values of DDAO 
phosphate.  This indicates that, unlike previously believed, DDAO phosphate is a 
noncompetitive inhibitor and, therefore, not useful for this system.  The led us to pursue 
other possible inhibitors. 
 Dr. Jim Wild recommended the use of coumarin derivatives as possible 
inhibitors.  On the recommendation by Dr. Alex Simonian that coumarin 1 was a 
competitive inhibitor; we investigated coumarin 1 for its fluorescent properties.  We 
found that coumarin 1 has an excitation maximum at 390 nm and an emission maximum 
at 468 nm. 
 We gold labeled the enzyme and tested the enzyme activity.  We found that the 
enzyme had lost >90% of the activity upon labeling for all gold attachments.  With such 
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low activity it was difficult to quantify exact values.  An important thing to note is that it 
is possible that activity loss does not necessarily indicate loss of binding.  So it is 
possible that enzyme will still be useful as a sensor with no catalytic properties.  If not 
then we will need to address other ways of introducing gold into the system.  This could 
be done by immobilizing both the enzyme and gold colloid into a hydrogel network that 
would encapsulate the enzyme/gold mixture, but still allow for diffusion of target and 
decoy into the hydrogel.  Another problem with the system is that we require moderately 
high concentrations of gold-labeled enzyme in the system (>100 µM, assuming that the 
binding affinity has not be decreased).  During the production of the gold-labeled 
enzyme, the enzyme solution is only around 1µM.  However, this can be overcome by 
concentrating the enzyme via centrifuge filtration, and then immobilizing a small volume 
in the light path of the fluorometer (to compensate for the very low required volume).  To 
do this, we had to incorporate a second, noninterfering fluorophore into the mixture to 
allow for normalization.  For this, Texas Red was chosen (ex: 510 nm, em: 615 nm). 
 Initial attempts at performing the hydrogel immobilization have been 
unsuccessful.  While coumarin 1 has responded well to the polymeric environment, 
Texas Red appears to be quenched by the polymer.  Furthermore, creating a thin, 
immobilized polymer film has created the problem that the path length in the fluorometer 
has now been decreased from 1 cm to <1 mm.  To overcome this problem, we are 
investigating a more three-dimensional immobilization into a smaller volume centered 
about the light path.  In doing so, we hope to increase the light path to approach 1 cm 
while still maintain a small sample volume. 
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Conclusions  
 While we are still optimistic that the system will work, we have come to realize 
that there are certain issues we did not and could not have predicted.  While we will 
continue to exhaust all options using the Nanoprobes gold system (since it creates are 
very closely, specifically bound gold), we realize that in may be necessary to investigate 
other immobilization techniques that would lock the gold into the hydrogel network 
without directly interacting with the enzyme. 
 Even if the system is altered to use a different gold product, the incorporation of a 
second, noninterfering fluorophore is a crucial technique.  This will lend itself to making 
the final product (a portable, self-contained biosensing apparatus) more robust.  The 
second fluorophore present for normalization allows for simpler optical alignment in the 
final system. 
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CHAPTER VI 
 
FEASIBILITY OF DEVELOPING A SERS BASED SENSOR PLATFORM FOR 
SPECIFIC DETECTION OF β-AMYLOID 
 
Introduction 
The goal of this work is to examine the feasibility of the development of a new 
detection platform and methodology for early detection and characterization of β-
amyloid peptide (Aβ), the primary protein component of senile plaques in Alzheimer's 
disease (AD).  Definitive diagnosis of AD is still by postmortem examination of central 
nervous tissue for evidence of amyloid plaques and neurofibrillary tangles.  Probable 
diagnosis is made based on tests of cognitive function, MRI, and functional PET.  
Currently, a number of investigators are developing fluorescent or PET imaging agents 
specific for Aβ that could be used for in vivo, pre mortem diagnosis of AD [91, 174 - 
176].  In addition, a number of investigators are developing 2-D electrophoresis/mass 
spectrometry methods to look for early markers of AD in cerebral spinal fluid [98, 177 - 
204].  However, at present, there are still no approved definitive tests for AD premortem. 
A unique product has been developed by Nanospectra Biosciences that 
incorporates nanoshells on a surface providing a robust platform for analyte detection at 
trace levels using surface enhanced Raman spectroscopy.  A variety of evidence 
indicates that Αβ peptide, in specific aggregation states, can be found in cerebral spinal 
fluid, and may be able to be used as a marker for AD progression [183, 187, 192, 199 – 
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201, 204].  For a SERS sensing strategy to be successful, an affinity surface for Aβ must 
be designed that is molecularly small, has high affinity for Aβ, has low affinity for 
irrelevant proteins, and whose spectral features do not significantly overlap with 
structure specific features of the Aβ Raman vibrational spectra.  The development and 
testing of such an affinity surface is described. 
 
Surface enhance Raman spectroscopy (SERS) 
Surface Enhanced Raman Spectroscopy (SERS) is a Raman Spectroscopic 
technique that provides greatly enhanced Raman signal from analyte molecules that have 
been adsorbed onto certain specially prepared metal surfaces. Increases in the intensity 
can be as high as 108 and 1014 for some systems [46, 47].  Furthermore, the fact that 
SERS is surface-dictated spectroscopic technique justifies the use of SERS as a sensor 
platform. 
 
Aβ structure associated with Alzheimer’s disease 
 Aβ is a 39 to 43 amino acid long peptide that aggregates both in vivo and in vitro 
to form a variety of structures reported to be toxic and/or disease associated.  These 
structures include a non-fibrillar species of approximately 17 to 42 kDa referred to as 
amyloid derived diffusible ligands (ADDLs) [90], protofibrils species [205] and fibril 
species.  All the disease associated oligomers of Aβ have a high beta sheet content, in 
contrast to non-disease associated species.  The currently most aggressively pursued Aβ 
oligomer target for both diagnostics and therapeutics is the ADDL [206].    
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In vivo, Aβ is known to accumulate in the cerebral cortex during disease, with 
deposition into mature amyloid plaques first in the entorhinal cortex and the 
hippocampus then later in the frontal cortex [91].  During disease, it is apparent that Aβ 
accumulates in other parts of the body that are easier to sample for in vitro diagnostic 
measurements [207].  Aβ circulates in both the blood and the cerebral spinal fluid. As 
disease progresses, there are significant changes in oligomeric Aβ in the cerebral spinal 
fluid [208 - 210]. 
 
Relationship between sialic acid and β-amyloid 
While many investigators are developing structure specific antibodies for 
detection of disease associated Aβ [211-213], there may be biomimetic materials that 
can be developed with antibody like affinity but smaller molecular size, that may be 
more appropriate for the demands of a SERS based sensing system.  A variety of 
evidence indicates that β-amyloid may bind to cells via an interaction with surface 
glycolipids or glycoproteins, and that the affinity of this interaction increases when the 
gangliosides or sialic acid molecules on the cell surface are clustered.  [214-221].  Based 
on these data, we hypothesized that biomimetic surfaces could be synthesized which 
would reproduce the clustered sialic acid structure of the cell surface, and therefore 
recreate the Αβ binding seen to occur on neuronal cell membranes.  
Using all the principles previously described, we have successfully proven the 
capability of SERS as a sensor platform.  Furthermore, we have developed and 
characterized numerous surfaces for both binding affinity to Aβ and binding capacity 
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(both of which are important characteristics for a SERS-based sensor).  Combining this 
information, we have all the background necessary to justify moving forward into SERS-
based sensor development. 
 
Materials and methods 
Materials 
 The Aβ (1-40) was synthesized and purified by BioSource International 
(Camarillo, CA). The sequence is DAEFRHDSGYEVHHQKLVFFADVGSNKG-
AIIGLMVGGVV.  Molecular mass and purity were confirmed by mass spectroscopy 
and reverse phase HPLC (MW = 4356, >95 % purity).  Bovine serum albumin (BSA) 
was purchased from Fisher Scientific (Fairlawn, NJ).  The nanosphere gold substrates (to 
be referred to as “slides” henceforth) were supplied by Nanospectra Biosciences, Inc. 
(Houston, TX).  The IODO-beads, G-5 desalting columns, 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide Hydrochloride (EDC), and sulfosuccinimydyl-3-(4-
hydroxyphenyl) propionate (sulfo-SHPP) were purchased from Pierce Biotechnology, 
Inc. (Rockford, IL).  The 125I and G-25 Sephadex were purchased from Amersham 
Biosciences/GE HealthCare (Piscataway, NJ.).  Disialyllacto-N-tetraose (DSLNT) was 
purchased from V-labs, Inc. (Covington, LA).  The glycidyl methacrylate and tetrabutyl 
ammonium bormide were purchased from Acros Organics (Geel, Belgium).  5-
(aminomethyl)fluorescein (5-AMF) was purchased from Molecular Probes (Eugene, 
OR).  Scintillation counting was done using a Wallac MicroBeta Jet microplate 
scintillation counter from PerkinElmer Life and Analytical Sciences  (Shelton, CT).  
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Sulfo-N-Hydroxy-Succinimido-Nanogold (sulfo-NHS-nanogold) and silver enhancing 
reagent were purchased from Nanoprobes (Yaphank, NY).  All other materials and 
chemicals were purchased from Sigma-Aldrich Corporation (St. Louis, MO). 
 The nanosphere slides from Nanospectra are designed to allow them to be tuned to 
the frequency of the laser being using in the Renishaw microRaman system.  The 
spheres have silica core around which gold is deposited layer by layer until the desired 
frequency is achieved. Figure 6.1 shows how the frequency of the spheres varies with 
shell thickness. 
 
 
Fig 6.1.  Relationship between absorbance and shell thickness for Nanospectra 
nanospheres.  The curves show the absorption characteristics of four different shell 
thicknesses.  As can be seen here, as the thickness increases, the absorption 
maximum blue shifts.  Obtained from www.nanospectra.com/physics/physics.asp. 
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Gold labeling and silver enhancing of generation 4.0 PAMAM dendrimer 
The procedures for the attachment of sulfo-NHS-nanogold to primary amines on 
the dendrimer were performed according to the peptide labeling procedure provided by 
Nanoprobes without modification [154].  The silver enhancement was performed 
according to the silver enhancement of nanogold for EM procedure from Nanoprobes 
without modification [154]. 
 
Collection of SERS spectra 
30 µl of each of the samples (sample 1 = Au-Ag-Dendrimer, sample 2 = Au-Ag-
Dendrimer-Aβ) were pipetted onto the surface of a microscope glass coverslip (22×22 
mm, Fischer Scientific Co.) and the water was allowed to evaporate for 30-45 min, until 
a thin solid crust of the sample remained on the surface of the coverslip. The coverslip 
was then placed onto the stage of the Leica DMLM microscope that was coupled to a 
Renishaw System 1000 Raman spectrometer. The laser used for the SERS studies was 
the 514.5 nm line of an Ar+ laser (Spectra Physics Model 263C) with approximately 5 
mW of laser power delivered to the sample. The incident laser beam was incident on the 
sample via the 50X air objective (NA =0.75) of the microscope. The SERS spectra were 
collected with the diffraction grating centered at 900 cm-1 and integration time of 90 
secs. 
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Formation of self-assembled monolayer (SAM) 
 All monolayers were formed using the same procedure.  The monolayer material 
was dissolved in ethanol to form a 2mM solution.  The slide was submerged in the 
ethanolic solution and allowed to react for 24 hours at room temperature.  The slide was 
then removed from the solution and rinsed thoroughly with ethanol and dried under 
nitrogen.  The monolayer materials used all had the following general form:  HS-R-
COOH, where R = (CH2)2, (CH2)10, or (CH2)15.  The exception to this rule is 4-
aminothiol phenol (4-ATP).  4-ATP has the following structure: HS-R-NH2, where R = 
benzene.  Figure 6.2 depicts how the self-assembly occurs.  FTIR was used to confirm 
the assembly of the monolayer.  Figure 6.3 shows a representative spectrum of a 
monolayer with relevant peaks pointed out. 
 
 
Fig 6.2. Schematic of self assembly process.  The monolayer compound floats freely in solution until 
coming in contact with the metaled surface (Ag, Au, or Ni usually).  Upon contact, the thiol reacts with 
the surface, covalently binding the molecule to the surface.  This layer is fluid in nature and will move 
around and continue to assemble until a tightly packed structure is created.  This creates the lowest energy 
state for the system and completes the self assembly process. 
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Fig 6.3.  FTIR spectrum of 11-MUDA SAM.  The most interesting peaks occurred at 1700 (carboxylic acid) 
and a doublet at 2849 & 2917 (CH2). 
 
 
Determination of monolayer stability 
One slide of each monolayer was placed in two different conditions:  in nitrogen, 
in the dark and exposed to light and air.  A third 16-MHDA slide was stored in nitrogen, 
but exposed to light to test for the effect of photobleaching the fluorophore.  After 24 
hour exposure, the surfaces were thoroughly rinsed with deionized water and dried under 
nitrogen before imaging using a fluorescence microscope.  The images were analyzed 
using Matlab. 
 
 
1700: -COOH
2849 & 2917: 
- CH2 - 
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Attachment of dendrimer or 5-AMF to carboxy-terminated monolayer 
 The dendrimers were attached using EDC chemistry described by Pierce 
Biotechnology [222] with minor modifications.  These modifications were the 
concentrations used (since the surface concentration of monolayer could not be known).  
The EDC was added to a concentration of 10 mg/mL (give molar concentration) with 
dendrimer or 5-AMF added to the same molar concentration and reacted overnight.  
Upon completion, the slide was rinsed thoroughly with deionized water and dried under 
nitrogen for storage.  Figure 6.4 shows the mechanism for EDC chemistry.  Figure 6.5 
represents a dendrimer surface.  Figure 6.6 represents the FTIR spectra from attaching 
dendrimer. 
 
 
 
Fig. 6.4.  Schematic of EDC chemistry.  The carboxylic acid-terminated compound reacts with EDC to form an 
amine-reactive intermediate.  This intermediate then reacts with the amine-terminated compound to create and amide 
bound leaving only the spent EDC. 
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Fig. 6.5.  Schematic of dendrimer surface.  The figure depicts a generation 4.0 
amine-terminated dendrimer attached to a carboxylic acid terminated surface (11-
MUDA) via EDC chemistry.  This leads to the formation of amide bounds. 
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Fig. 6.6.  FTIR spectra of 11-MUDA and 11-MUDA/Den 4.0 on surface.  The FTIR spectra of 11-MUDA (d, 
solid line) and 11-MUDA/Den 4.0 (thin, dashed line) show how the EDC chemistry works.  The strong 
spectrum from the dendrimer obscures any amide peaks that may have formed (due to secondary amides being 
present in the dendrimer).  However, the loss of the 11-MUDA peak at ~1700 indicates that there is a loss of the 
carboxylic acids at the surface.  This can be attributed to the formation of amides to link the dendrimer. 
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Production of DSLNT “artificial ganglioside” 
 A solution containing 100uL of deionized water containing 1mg DSLNT, 2.2uL 
triethylamine, 2.2uL glycidyl methacrylate, and 2.2mg tetrabutyl ammonium bromide 
was reacted overnight at room temperature.  The solution was then incubated at 60oC for 
one hour.  After cooling to room temperature, the solution was diluted to 1 mL of total 
volume with deionized water.  To the solution was added 15 mg of G-25 Sephadex to 
remove unreacted glycidyl methacrylate.  This purification is based on simple quenching 
procedures.  This works by introducing an excess of hydroxides to bind the excess 
methacrylate.  The mixture was incubated at room temperature for one hour.  The 
Sephadex was removed via centrifuge filtration over a 30 kDa membrane.  The filtrate 
was then lyophilized to produce a sticky solid.  The procedure was adapted from Leech 
et al [223].  The product of this reaction, a disialic acid terminated oligosaccharide with 
a methacrylate pendant group, could then be reacted with SAMs to make a disialic acid 
terminated monolayer, which is referred to as an artificial ganlioside in the following 
sections.  With all the available hydroxyl groups available on DSLNT (due to the entire 
structure being composed of sugars), it is not possible to predict where the glycidyl 
methacrylate will attach.  This makes representing the structure extremely difficult.  
However, Figure 6.7 represents the FTIR spectra of a)glycidyl methacrylate, b)DSLNT, 
and c)glycidyl methacrylate – DSLNT complex.  The location of peaks in the spectra 
indicates the success of the attachment chemistry. 
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Fig. 6.7.  FTIR spectra of a) glycidyl methacrylate, b) DSLNT, and c) glycidyl methacrylate – DSLNT 
complex.  The ester peak, epoxide peak, and aliphatic ether peak in the gylcidyl methacrylate are the peaks of 
interest.  In the  methacrylate – DSLNT complex, we see the presence of numerous peaks characteristic of 
DSLNT.  However, one thing we do notice is a strong ester peak without the presence of peaks from epoxides 
or aliphatic ethers. 
1152: Aliphatic Ether 
1300: Epoxide 
1722: Ester 
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Fig 6.7. continued 
 
From these spectra, you can see that the complex has both species present (as is clear 
from the characteristics of the DSLNT being present and the strong ester peak).  
However, the presence of the ester peak without the presence of the epoxide or aliphatic 
ester peaks indicates that the epoxide ring has reacted with the DSLNT, creating more 
ester bonds in the process. There is no noticeable decrease in the alcohol stretch from 
2500 – 3500.  This is due to the large number of alcohols available. 
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Production of GM1 ganglioside or artificial ganglioside surface 
 The ganglioside, GM1, or disialic acid terminated oligosaccharaide-methacrylate 
prepared as described previously was dissolved in hexane to a concentration of 0.1 
mg/ml and slowly pipetted over DI water in a Petri dish.  The hexane was allowed to 
evaporate, leaving the ganglioside or oligosaccharide on the surface of the water with the 
hydrophobic portion facing upward.  A slide with a SAM developed as previously 
described was dipped SAM-side down to just contact the water air interface, allowing 
the hydrophobic tail of the ganglioside/oligosaccharide to interact with the alkane 
portion of the monolayer.  The slide was then lifted away from the water and dried under 
nitrogen.  Figure 6.8 gives the representation of a ganglioside layer.  Representing the 
artificial ganglioside layer is again not possible (due to the large number of 
confirmations possible).  However, the general form of the artificial ganglioside 
monolayer should closely mimic that of the ganglioside layer.  FTIR spectra of the 
ganglioside and artificial ganglioside layers are shown in Figures 6.9 a and b. 
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Fig. 6.8. Schematic of a ganglioside surface.  The hydrophobic fatty acid tails of the 
ganglioside interact with the equally hydrophobic alkanes of the monolayer, tangling with 
them.  Upon drying, the surface is left with the hydrophilic sugar molecules protruding from 
the monolayer while the hydrophobic tails stay embedded in the SAM. 
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Fig 6.9.  FTIR spectra of a) GM1 and b) artificial ganglioside layers.  The peaks of interest are labeled to indicated 
successful formation of the monolayers.   The most interesting peak is at 1016 for the artificial ganglioside and 
1040 for the GM1 ganglioside.  These represent alicyclic alcohol peaks.  The dark line represents the 11-MUDA 
monolayer and the dsshed lines represent the monolayer and ganglioside conjugate. 
1040: Alicyclic alcohols 
1040: Alicyclic alcohols 
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Production of sialic acid labeled monolayer 
 The sialic acid was attached to amine terminated SAM using EDC chemistry 
described by Pierce Biotechnology [222] with minor modifications as described in the 
previous section.  The EDC was added to a concentration of 10 mg/mL (give molar 
concentration) with sialic acid added to the same molar concentration.  The monolayer 
used in this procedure was the amine-terminated 4-ATP.  FTIR analysis of this sample 
was not performed due to limited material availability.  However, successful labeling of 
the layer seems likely from previous success and binding studies presented later. 
 
Stability of fluorecein labeled monolayer  
 The fluorescein monolayer was developed my creating 3-MPA, 11-MUDA, and 
16-MHDA monolayers as previously described.  The fluorescein was attached using 
standard EDC chemistry.  The fluorescein slides were then a image used standard 
fluorescent microscopy techniques while employing a fluorescein filter.  The field of 
vision used during analysis was kept constant at approximately a 3mm diameter circle.  
The images were then analyzed using Matlab. 
 
Radiolabeling  of β-amyloid 
 Aβ(1-40) was radioiodinated via a modified Bolton Hunter method.  This method 
of iodination was chosen to preferentially label at the N terminus of the peptide.  
Labeling at other primary amines was inhibited by maintaining the pH below the pKa of 
those residues.  100 nmol of sulfo-SHPP was iodinated with 200 µCi of 125I using the 
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IodoBead catalyst.  The reaction was carried out for 15 minutes in pH 8 borate buffer in 
a volume of 140 µL.  The catalyst was removed and 10 nmol (100 µL) of freshly 
prepared β-amyloid(1-40) (in water) was added to the iodinated sulfo-SHPP.  The 
reaction was allowed to proceed for 3 hours at 4 C.  The resulting condensation product 
was separated from free 125I using a G-5 desalting column which also fractionated the 
peptide.  The peptide was eluted from the column with phosphate buffer and stored at 
4oC until use.  Iodinated Aβ(1-40) was typically used within one month of preparation. 
The free activity associated with radiolabeled Aβ(1-40) was determined by precipitation 
of the peptide with 5 wt% phosphotungstic acid in the presence of 5 mg/ml bovine serum 
albumin.  Precipitable activity was 70 to 80%.   
 Peptide concentration was determined from the activity of the 125I-labelled  
Aβ(1-40) by assuming that 50% of the peptide was recovered in from the desalting 
column using one column volume of the eluting buffer and that the peptide concentration 
was proportional to the precipitable activity of that fraction. No attempt was made to 
remove unlabelled peptide from labeled peptide.  Relative aggregation state of the 
peptide was assessed using native polyacrylamide gel electrophoresis, counting activity 
of sliced sections of gel to determine relative abundance of different molecular weight 
species.  The iodinated peptide was approximately 70% monomer or dimer, with the 
balance being large (above 100 kDa) aggregate. 
 
Determination of binding affinity (KAβ) and surface saturation (Nsat) 
Freshly prepared nanogold-monolayer surfaces were incubated with sufficient 
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125I-labeled Aβ(1-40) to completely wet the surface (typically 120 µL) at a constant 
temperature with rocking for two hours.  Bovine serum albumin was added at a final 
concentration of 1 mg/ml to block nonspecific binding.  Free Aβ(1-40) was removed 
from the surface, then the surface was washed twice with phosphate buffered saline.  
The bound surface was removed from the glass slide using a cotton swab.  The activities 
of free peptide and bound surface (plus cotton swab) were counted separately, and 
binding constants were determined from equilibrium binding isotherms via fitting to a 
langmuir isotherm (Equation 6.1) using a non-linear least squares regression using 
Polymath 5.0.  
freeA
satfreeA
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β
β
β
+=    (6.1) 
where:  Nbound = nanomoles of Aβ on surface 
 KAβ = equilibrium binding coefficient (M-1) 
[Aβ]free = concentration of Aβ in solution at equilibrium 
Nsat = nanomoles of Aβon surface at saturation 
 
Results and discussion 
Determination of SERS detection feasibility 
 The first step of this study was to determine two things. The first is whether 
Aβwould give an acceptable signal through SERS.  The second was to determine if the 
signal from the recognition unit (dendrimer, ganglioside, etc.) would interfere with the 
signal from the Aβ. 
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 These two things were determined by first gold labeling the dendrimer and then 
silver enhancing the dendrimer after reacting with Aβ fibrils (dendrimer and Aβ at 
100µM concentrations in PBS at pH = 7.4).  The SERS analysis was performed by 
Mustafa Chowdhury in Dr. Gerry Coté’s lab at Texas A&M University.  The results of 
this study can be seen in Figure 6.10. 
 
Fig 6.10.  SERS feasibility study.  A representative SERS spectrum for the dendrimer alone (gray 
line) and the dendrimer bound to Aβ (black line) are shown.  Several peaks are present in the Aβ 
spectrum that are not present with just the dendrimer.  The area of most interest occurs in the 
1350-1400 range.  This area is indicative of amide bonds (a very strong signature in amyloid 
proteins that provide structure information). 
 
 
 In the spectral region from 1350-1400 cm-1 in Figure 6.10, the dendrimer 
spectrum has a peak at 1386 cm-1 indicating the presence of amides in the internal 
structure of the dendrimer.  However, the peak shifts to around 1352 cm-1 when Αβ is 
preesent, indicating the presence of amides in a β-sheet structure.  Both the presence of  
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Αβ and information on its structure are needed for an effective diagnostic for 
Alzheimer’s disease.  The amide region of the Raman spectra can be used for structure 
determination of Αβ [224, 225].  The shifting of this peak and its clear presence with 
dendrimer present indicates a SERS based sensor that incorporates a dendrimer as 
recognition element for Αβ is both reasonable and feasible. 
 
Effect of distance from surface on SERS signal 
 It was important to recognize the impact that distance has on SERS.  We 
analyzed this behavior by attaching aniline (a very strong Raman active substrate) to the 
ends of three different monolayers (3-MPA, 11-MUDA, and 16-MHDA) using EDC 
chemistry.  We then analyzed the aniline Raman signal from the surfaces to determine 
how the aniline SERS signal intensity changed with distance from the surface.  Figure 
6.11 shows the behavior. 
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Fig 6.11.  Distance dependence of SERS intensity.  The system tested had aniline attached to different length 
alkanethiol SAMS.  A linear fit to the data gave the trend line indicated on the graph. 
 
 
Using the equation 6.2 to describe the SERS intensity: 
n
r
xr
aI 


 −=       (6.2) 
where: a is some scaling factor 
 r is the radius of the particle 
 x is the length of the spacer arm (distance from surface) 
 n is the power for the distance decay 
The numerator of equation 6.2 expands to Pascal’s Triangle (Figure 6.12), which is as 
follows: 
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Fig 6.12.  Pascal’s Triangle.  This triangle represents the 
expansion of  equation of the form (x-y)n.  This figure 
represents the first 5 expansions. 
 
 
These numbers represent the coefficients of subsequent r and x terms (where the 
exponent of r decreases as you go from left to right).  Since r >> x, we can reduce any of 
these expansions to first two terms of the form in equation 6.3. 
 
rn + C2 r(n-1)x       (6.3) 
 
where:  C2 is the second term in the row 
By substituting into the general SERS dependence equation, we arrive at equation 6.4. 
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Which reduces to (equation 6.5): 
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This means that intensity should be linear with x if the system fits this form.  Figure 6.11 
shows the linear relationship of the data.  From the equations described previously, we 
can see that the y-intercept is “a”, and the slope is aC2/r.  From the trend line values for 
slope and intercept, we conclude that a = 667 and C2 = 3.08 (assuming the particle radius 
is 75nm, as is true in our system).  Referencing back to Pascal’s Triangle to arrive at a 
3rd order distance dependence for the substrate we are using. 
 
Monolayer stability 
 Literature indicates that monolayers are unstable in the presence of oxygen [226].  
This is due to the reaction of oxygen with sulfur at the metal surface.  This causes the 
formation of sulfates (which no longer bind to the gold surface).  To test the stability of 
the monolayers on proprietary gold nanoshell surfaces made by Nanospectra, we formed 
standard monolayers of 3-mercaptopropionic acid (3-MPA), 11-mercaptoundecanoic 
acid (11-MUDA), and 16-mercaptohexadecanoic acid (16-MHDA) and then attached 5-
AMF as described above.  The result of this analysis can be seen in Figure 6.13. 
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Fig 6.13. 24 hour monolayer degradation study.  The surfaces were exposed to both light and air unless 
otherwise noted.  The arbitrary pixel intensity is normalized based on the highest surface signal 
(MHDA, N2, Dark).  The error bars represent a one standard deviation for the data.  All samples have 
n>10,000.  All means are statistically different from one another based on studentized t-tests (p < 
0.00025). 
 
 
 As seen in Figure 6.13, the signal intensity for all three monolayer types (3, 11 
and 16 carbon chains) that fluorescence signal intensity from the attached fluorescein 
were equivalent at the first measurement within experimental error when stored in 
nitrogen in the dark. All three monolayers also showed similar loses of  surface signal 
after 24 hours when stored in air in the light, with the fluorescence signal loss ranging 
from 39% for 11-MUDA to 58% for 3-MPA.  Exposure to just light (MHDA, N2) led to 
no appreciable degradation of the surface, while exposure to just air (MHDA, Dark) led 
to similar levels of signal loss and surface degradation as exposure to both nitrogen and 
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light.  These results suggest that the monolayer with fluorescein attached degrades 
significantly in the presence of air. 
Degradation of the fluorescein-SAM was followed as a function of time in both 
the presence and absence of air, as shown in Figure 6.14.   
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Fig. 6.14.  Long term monolayer degradation study.   The study was performed by storing in the appropriate 
environment in between readings.  The slides were rinsed and dried before each reading.  Open symbols 
represent slides stored in air and light, and filled symbols represent slides stored in N2 and dark (unless 
otherwise noted).   The symbols and lines are as follows: filled diamond and solid line, 16-MHDA in light; 
open diamond and solid line, 16-MHDA in dark; circle and dashed line, 16-MHDA; triangle and dotted line, 
11-MUDA; square and broken dashed line, 3-MPA. Error bars represent one standard deviation. 
 
 
 As can be seen from Figure 6.14, all samples stored in similar environments 
showed similar amounts of degradation with time (within experimental error).  This was 
 111
determined by analyzing a linear curve fit to the data points.  The degradation appears to 
be zero order indicating the rate is only related to oxygen concentration.  Samples that 
were stored in nitrogen showed similar degradation rates but lower total degradation than 
those stored in air.  This is can be attributed to the fact that 1) the surfaces exposed to air 
continuously had less surface to lose after 24 hours than those stored in nitrogen and 2) 
the washing and reading procedures allowed the samples stored in nitrogen to be exposed 
to air for considerable lengths of time.  
 While these results clearly indicate that fluorescein labeled monolayers degrade or 
detach from the gold surface as a function of time, and that degradation, at least initially, 
is faster in air than in the presence of nitrogen, they do not indicate at what position in the 
monolayer degradation occurs.  Degradation could be at the amide bond where 
fluorescein was attached to the SAM, or more likely, at the gold surface, where the sulfur 
attaches to the gold.  Others have shown that oxidation occurs at this position [226]. 
 
Determination of binding affinity (KAβ) and surface saturation (Nsat) 
 After analyzing the monolayer stability, we tested the binding affinity and surface 
capacity at saturation of different surfaces for β-amyloid.  The surfaces tested were as 
follows:  unblocked gold surface, unblocked 11-MUDA monolayer, blocked 11-MUDA 
monolayer, blocked dendrimer-labeled 11-MUDA monolayer (generations 2.0, 3.0, and 
4.0), blocked artificial ganglioside layer, blocked GM1 ganglioside layer, blocked 4-ATP 
monolayer, and blocked sialic acid-labeled 4-ATP monolayer.  The Langmuir binding 
isotherm fits to these surfaces can be seen in Figures 6.14-6.17. 
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Fig. 6.15. Binding isotherm for unblocked gold, unblocked 11-MUDA, and blocked 11-
MUDA.   The symbols represent the experimental data, while the lines represent the calculated 
langmuir isotherms. The symbols and lines are as follows: ♦ and solid line – unblocked gold; ■ 
and small dashed line – unblocked monolayer; ▲ and large dashed line – blocked monolayer. 
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Fig. 6.16. Binding isotherm for blocked 11-MUDA monolayers with dendrimer 
generations 2.0, 3.0, and 4.0.  The symbols represent the experimental data, while the 
lines represent the calculated langmuir isotherms. The symbols and lines are as follows: ♦ 
and solid line – generation 2.0; ■ and small dashed line – generation 3.0; ▲ and large 
dashed line – generation 4.0. 
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Fig. 6.17. Binding isotherm for blocked 4-ATP monolayers with and without sialic acid 
attached, GM1 ganglioside layers, and artificial ganglioside layers.  The symbols 
represent the experimental data, while the lines represent the calculated langmuir 
isotherms. The symbols and lines are as follows: ♦ and solid line – 4-ATP; ■ and large 
dashed line – 4-ATP with sialic acid; ▲ and small dashed line – GM1; ● and slternating 
dashed line – artificial ganglioside. 
 
 
 From these isotherms, it was possible to obtain values for KAβ and Nsat for each 
surface.  The results can be found in Table 6.1. 
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Table 6.1.  Summary of binding information for different surfaces 
Substrate            KAβ  (M-1) Nsat  (pmoles)
Gold Surface 1.05 ± 0.02 x 106 69.3 ± 0.8 
11-MUDA 3.2 ± 0.3 x 107 4.3 ± 0.2 
Blocked 11-MUDA 5.0 ± 0.1 x 105 20.0 ± 0.8
Blocked Gen 2.0 7.2 ± 0.7 x 106 1.85 ± 0.08 
Blocked Gen 3.0 7.1 ± 0.5 x 106 3.0 ± 0.1
Blocked Gen 4.0 6.9 ± 0.4 x 106 2.89 ± 0.08
Blocked artificial ganglioside 3.471 ± 0.001 x 107 0.5222 ± 0.0001
Blocked GM1 ganglioside 2.4 ± 0.8 x 107 0.6 ± 0.1
Blocked 4-ATP 3.1 ± 0.3 x 106 2.0 ± 0.4
Blocked sialic acid 6 ± 3 x 108 0.261 ± 0.005
Blocked Gen 2.0/SA 1.01 ± 0.03 x 107 N/A
Blocked Gen 3.0/SA 1.1 ± 0.8  x 107 N/A
Blocked Gen 4.0/SA 2.5 ± 0.7  x 107 N/A
 
95% Confidence intervals for each constant has the same units as the constant to which they apply. 
 
 
As seen in Figure 6.15 and Table 6.1, the unmodified gold surface was capable of 
binding the greatest amount of Aβ, approximately 70 pmols, but without specificity.  
Experiments were done with the unmodified gold surface to determine the upper limit of 
binding capacity for the system.  A comparison of the two  11-MUDA surfaces (blocked 
and unblocked) shows that the self assembled monolayer has a relatively high binding 
capacity for Aβ, however, the addition of BSA leads to a 100 fold decrease in binding 
affinity, suggesting that the binding observed was nonspecific.  In preparation of all other 
binding isotherms, BSA was used to block nonspecific binding. 
  All three generations of dendrimer show specific binding to Aβ at around a value 
of KAβ of 7 x 106 M (Figure 6.16, Table 6.1).  Comparing this to a highly specific 
molecule, like an antibody (K = 1 x 109 M), indicates that the dendrimer is 
approximately two orders of magnitude less specific.  This indicates that there is room 
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for improvement.  From patent data, we estimate that the binding affinity of the 
PAMAM dendrimers for infectious prions to be on the order of 108 M-1 [227].  Both Aβ 
and infectious prions form extended β-sheet (amyloid) structures, thus is it possible that 
binding affinity of the dendrimers may be higher for more aggregated Aβ species. 
Also of note is the binding capacity for the dendrimers.  Generation 3 and 4 
dendrimers have the same binding capacity for Aβ, while generation 2 binds 
significantly less Aβ at saturation.  Given that we infer that the binding of Aβ to the 
unmodified dendrimers is via electrostatic interactions and the larger generation 
dendrimers have greater charges, this difference in binding capacity was expected.   
Similar trends have been shown for oligonucleotides binding to dendrimers via 
electrostatic interactions [228].  Total binding capacity at saturation may be important in 
determining limits of detection of Aβ via a SERS based sensor. 
A variety of evidence suggests that Aβ binds specifically to gangliosides on the 
cell surface; therefore we made a number of ganglioside-like surfaces that could be used 
in our sensor platform.  As seen in Figure 6.17 and Table 6.1, all of the sialic acid 
containing surfaces had greater binding affinity than the surfaces that did not contain 
sialic acid.  Furthermore, as the amount of sialic acid per structure increased, so did the 
binding affinity (SA > AG > GM1).  This is expected with the sialic acid surface 
approaching the “perfect” clustered surface.  It’s possible that by increasing the chain 
length of the monolayer, we may be able to increase the binding affinity of the surface. 
Work by Kakio and others [229-231] demonstrated that Aβ has an affinity on the order of 
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106 M-1 for GM1 gangliosides which contain sialic acid residues (an order of magnitude 
less than what we were able to achieve).  Affinity was highest for gangliosides with 
several sialic acid residues and when the gangliosides were clustered together in 
cholesterol rich microdomains, with affinity values in excess of 107 for tetrasialated 
gangliosides [231].  These numbers are comparable to what we found when designing the 
therapeutic dendrimer.  As for the artificial ganglioside, it shows a five fold increase in 
binding affinity over the dendrimer alone and a 3 fold increase in the binding affinity of 
sialic acid-labeled dendrimer.  This indicates that labeling the dendrimer is a step in the 
right direction, and that increasing the labeling ratio (currently only around 20%) could 
increase the dendrimer to levels comparable to those of gangliosides.  This work is 
currently being investigated. 
 
Conclusions 
 Initial investigations indicate that using SERS will work as a sensing system for 
the detection of β-amyloid.  SERS shows both high sensitivity and structural analysis 
allowing for the determination of the structure of the bound protein.  However, the 
system is going to be dependant upon the size, selectivity, and binding capacity of the 
recognition molecule being used. 
 It appears that by labeling the dendrimer with sialic acid, we are able to produce a 
molecule that is both highly selective for Aβ (KAβ > 1 x 107 M) and closely mimics the 
cell surface structures (gangliosides).  With some further work and turning, the system 
could prove to be more effective than just using gangliosides or sialic acid monolayers as 
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recognition molecules (since the dendrimer will effectively increase the surface area for 
binding.   
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CHAPTER VII 
 
ATTENUATION OF β-AMYLOID INDUCED TOXICITY BY SIALIC ACID-
CONJUGATED DENDRITIC POLYMERS 
 
Overview 
Beta-amyloid (Aβ) is the primary protein component of senile plaques in 
Alzheimer’s disease and is believed to be associated with neurotoxicity in the disease. 
We have shown that Aβ binds with relatively high affinity to clustered sialic acid 
residues on cell surfaces and propose that artificial sialic acid clusters conjugated to 
dendritic polymers can compete with clustered sialic acid residues on cell surface 
gangliosides for Aβ binding. In the current work, we assess the ability of these sialic 
acid conjugated dendrimers to prevent Aβ toxicity. Flow Cytometry was used to analyze 
viability of SH-SY5Y neuroblastoma cells and the effects of soluble and clustered Sialic 
acid mimics on Aβ cell toxicity. Soluble Sialic acid attenuation of Aβ induced toxicity 
are highly Aβ concentration dependent and less effective at higher concentrations. The 
clustered Sialic acid mimics are more effective at protecting cells from Aβ toxicity at the 
higher concentrations of Aβ and looks promising as a possible therapy. This work may 
lead to and increased understanding of the mechanism of Aβ-sialic acid or ganglioside 
interaction, which is the first step towards developing therapeutic agents for prevention 
of Alzheimer’s disease. 
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Introduction 
 Alzheimer’s disease (AD) is the leading cause of neurodegeneration in the 
United States, affecting approximately 4.5 million Americans in 2003 [232], with an 
annual cost of care for these individuals estimated at over $100 billion [233]. This study 
cites figures based on 1991 data, which were updated in the journal’s press release to 
1994 figures, cited in 2001 – 2002 Alzheimer’s Disease Progress Report [234]. One of 
the pathological hallmarks of AD is the formation of amyloid plaques in the cerebral 
cortex, the primary protein component of which is the 39-43 amino acid peptide β-
amyloid (Aβ) [235].  Aβ, in a number of aggregated states including fibrils, protofibrils, 
and spherical oligomers, has been shown to be toxic to neurons and neuron like cells in 
culture [99, 236, 237].  It is believed that Aβ may play a major role in neurodegeneration 
associated with AD.  To that end, agents which either sequester Aβ or interfere with Aβ 
interaction/binding to cells have been sought after as a means to reduce the pathological 
effects of Aβ [97, 101−104]. 
A variety of evidence indicates that Aβ may bind to cells via an interaction with 
surface glycolipids or glycoproteins [100, 217, 229, 231, 238-241], and that the affinity 
of this interaction increases when the gangliosides or sialic acid molecules on the cell 
surface are clustered [229, 231].  Based on these data, we hypothesized that membrane 
mimics could be synthesized which would reproduce the clustered sialic acid structure of 
the cell surface, and therefore compete with the cell surface for Aβ binding.  To that end, 
we prepared sialic acid conjugated dendritic polymers and tested their ability to attenuate 
Aβ toxicity in a cell culture model.  The sialic acid conjugated dendritic polymers were, 
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in all cases, more effective than polymer alone at reducing Aβ toxicity.  Attenuation of 
Aβ toxicity was achieved at lower concentrations for sialic acid conjugated dendrimers 
with greater sialic acid functionality when compared to dendrimers with lower sialic acid 
functionality.  These results could have implications for the design of new agents that 
bind pathogenic Aβ peptides for the treatment of neurodegenerative disease.  
 
Materials and methods 
Materials 
 Aβ(1-40) was purchased from Biosource International (Camarillo, CA). Human 
neuroblastoma SH-SY5Y cells and rat pheochromaocytoma PC12 cells were purchased 
from ATCC (Manassas, VA). Cell dissociation buffer and cell culture reagents were 
purchased from Gibco-Invitrogen (Grand Island, NY). Propidium iodide (PI) was 
purchased from Molecular Probes (Eugene, OR). Human recombinant nerve growth 
factor – β (NGF-β), sialic acid ( N-Acetylneuraminic acid) and polyamidoamine 
(PAMAM) dendrimer polymers generation 2.0, 3.0 and 4.0 were purchased from Sigma-
Aldrich (St. Louis, MO). 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
Hydrochloride (EDC) was purchased from Pierce Biotechnology (Rockford, IL).  
Ultrafiltration membranes were purchased from Millipore (Billerica, MA).  All other 
chemicals were purchased from Sigma-Aldrich. 
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Peptide preparation 
 Aβ(1-40) stock solutions were prepared by dissolving the lyophilized peptide in 
one of two solvents, either 0.1% (vol/vol) trifluoroacetic acid in water or anhydrous 
dimethyl sulfoxide (DMSO) to make 10 mg/ml stock solutions. After incubating for 30 
minutes to 1h at 25oC, the peptide stock solutions were diluted to a concentration of 0.5 
mg/ml in sterile phosphate-buffered saline (PBS; 0.01 M NaH2PO4, 0.15 M NaCl, pH 
7.4) with antibiotics. These solutions were rotated at 25oC for 24 h. These solutions were 
further diluted to the final concentrations of between 5 and 20 µM in sterile medium and 
rotated for an additional 24 h prior to being added to cells.  Alternatively, stock solutions 
of Aβ were diluted directly to their final concentrations in sterile cell culture medium 
and rotated at 25oC for 24 h prior to addition to cells.  Both methods of peptide 
preparation yielded Aβ fibril and other aggregated species containing samples that were 
consistently toxic to cells in culture culture [242, 243].  
 
Cell culture 
 For experiments involving free sialic acid, rat pheochromaocytoma PC 12 cells 
were used. These cells were cultured in RPMI medium supplemented with 10% (vol/vol) 
horse serum, 5% (vol/vol) fetal bovine serum, 3 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin and 2.5 µg/ml amphotericin B (fungizone) in a humidified 5% 
CO2/air, 370C incubator. 
 For all other experiments, human neuroblastoma SH-SY5Y cells were used.  
Cells were cultured in a humidified 5% CO2/air incubator at 37oC in MEM, 
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supplemented with 10% (vol/vol) fetal bovine serum, 2.2mg/ml NaHCO3, and 
antibiotics/antifungals at the same concentrations as used with PC12 cells. SH-SY5Y 
cells were NGF differentiated prior to use in toxicity experiments by addition of 20 
ng/mL NGF to cells for 5-7 days. 
 
Synthesis and purification of sialic acid-conjugated dendritic polymers  
 Sialic acid was conjugated to amine terminated PAMAM dendrimers using EDC 
chemistry [222].  Sialic acid and EDC were both dissolved in 2mL of DI water to final 
concentrations of 30 mg/mL (200 mM). This system was allowed to react for 1 h at room 
temperature.  After one hour, dendrimer was added to a final concentration of 2mM.  
The reaction was then allowed to continue overnight to reach completion.  The reaction 
solution was then ultrafiltered using 1000 NMWL filters using the Millipore Model 8003 
Ultrafiltration Stirred Cell to remove unreacted sialic acid and EDC.  The reaction 
mixture was ultrafiltered using six 2 mL washes of DI water, such that the final 
concentration of free sialic acid in the mixture was less than 6% of the total sialic acid 
(free and covalently bound to dendrimer). Reduction of sialic acid levels in the washes 
was verified using UV absorbtion at 250 nm. After purification, the sialic acid 
conjugated dendrimer was resuspended in DI water for later use. Verification of the 
presence of sialic acid on dendrimers was done by FT-IR spectroscopy using a 
ThermoNicolet Avatar 3710 FTIR with Pike Miracle ATR Accessory (Thermo Electron 
Corporation, Waltham, MA).  As seen in Figure 7.1, peaks at 1034 cm-1, 1380 cm-1 and 
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between 2700 cm-1 and 3100 cm-1 confirm the presence of alcohols and acids consistent 
was a sugar and loss of primary amines from the reaction of the dendrimer with the acid. 
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Fig. 7.1. FTIR of conjugated and unconjugated PAMAM dendrimer generation 3.0.  The FTIR spectrum of 
unconjugated dendrimer (solid line) shows a characteristic doublet between 2700 and 3100 cm-1 representing 
the primary amines of the dendrimer termini.  For the conjugated dendrimer (dashed line), along with the 
disappearance of the amine doublet, which indicates a “capping” of the primary amines by sialic acid, there are 
the appearance of peaks at 1380 and 1034 cm-1 from the C-O-C structure and alicyclic alcohols from sialic acid, 
respectively.   
 
Toxicity assays 
MTT assay 
 PC 12 viability was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction assay. Viable, redox-active cells reduce MTT to 
a colored formazan product, the formation of which is generally linearly related to the 
1034 
1380 
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concentration of viable cells within the population. For these experiments cells were 
plated at a density of 105 cells/ well in a 96 well plate. After 24 h, the medium in each 
well was replaced with the Aβ peptide solutions and sialic acid and then incubated for 
another 24 h at 37oC.  MTT was then added to the medium to yield a final concentration 
of 0.5mg/ml in each well. The cells were allowed to interact with the MTT for 4 h, after 
which 100 µL of 5:2:3 N,N-dimethylformamide/SDS/water solution (pH 4.7) was added 
to dissolve the formed formazan crystals. After 18 h in a humidified CO2 incubator, 
absorbances were read at 585 nm  (Emax Microplate reader,Molecular Devices, 
Sunnyvale, CA).  Percent viability was determined by comparing absorbances for Aβ 
peptide or peptide-sialic acid treated samples to untreated controls.  The fractional 
increase in viability was estimated as viability of cells treated with both peptide and 
sialic acid relative to viability of cells just treated with Aβ peptide. 
 
PI assay 
 SH-SY5Y viability was measured by staining cells with PI, a nucleic acid dye 
that only binds to cells with permeable membranes, and measuring fluorescence of the 
cell population using flow cytometry.  SH-SY5Y cells were plated at a density of 2 X 
104 cells/well in 96 well plates and NGF differentiated.  After 7 days differentiation, 
culture medium was replaced with medium containing NGF and the compound to be 
tested, either Aβ, dendrimer, sialic acid, sialic acid conjugated dendrimer, or a 
combination of the above.  24 hours after addition of Aβ or other agent, cells were 
prepared for viability measurement by first detaching cells from the well by incubating 
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with 150 µL dissociation buffer at 250C for 15 minutes. 10 µL of 33 µM PI was added to 
each well and left to incubate at 250C for 20 minutes in the dark after brief shaking. 
Immediately after, cell fluorescence was measured with the FACSArray Bioanalyzer 
(Becton-Dickonson, Bedford, MA). Cells were excited with a 532 nm laser and 
fluorescence was detected using a 564-606 nm filter. Gating was done so as to obtain 
percentages of the total cell population that were viable.  Normalized viability values 
were obtained by dividing the percentage of viable cells in the sample by that in the 
control samples with no Aβ or other agent. 
 
Estimation of LD50 values and toxicity inhibition parameters. 
 LD50 values, defined here as concentrations of dendrimer or dendrimer sialic acid 
conjugate that led to a 50% reduction in cell viability,  were obtained by linear 
interpolation of viability as a function of concentration data about the region of 50% 
viability. The uncertainty of the concentration of dendrimer was estimated by 
determining the 95% confidence interval of concentration from the viability curves, and 
using that to determine a coefficient of variation of the measurement. 
In order to estimate the toxicity inhibition effects of dendrimers and sialic acid 
conjugated dendrimers, but also to take into account potential toxicity of the dendrimer 
constructs we developed the following empirical model (equation 7.1) that correlates the 
normalized viability (V), defined as the ratio of percentage of viable population in a 
sample to that in the sample with no Aβ or dendrimer present to the concentration of 
 126
sialic acid-conjugated dendrimer in terms of equivalent sialic acid (bound sialic acid 
(SA)) concentration: 
i
t
i K
SAk
KSA
VVSA
VV −+
−+= )( 0max0      (7.1) 
 
where  Vo is the viability at zero dendrimer-sialic acid complex concentration, Vmax is 
the maximum normalized viability, and Ki and kt are empirical constants associated with 
sialic acid binding to Aβ (and inhibition of its toxicity), and with the intrinsic toxicity of 
the dendrimer conjugates, respectively.  
It should be noted that this model does not take into account the concentration of 
Aβ and is therefore valid only for 50 µM Aβ. The data were fitted to the model and 
constants Vmax Ki and kt were estimated using the Levenberg-Marquardt non-linear 
regression method (Polymath 5.1, CACHE Corporation, Austin, TX) 
 
Results and discussion  
Attenuation of Aβ-induced toxicity by free sialic acid 
 Work from a number of laboratories suggests that Aβ binds to sialic acid 
containing gangliosides with a moderately high affinity [241, 244-247].  In our lab, we 
have previously shown that depletion of membrane-associated sialic acid residues or 
inhibition of sialic acid-containing ganglioside synthesis protects PC 12 cells from Aβ-
induced toxicity [217]. Based on these results, we hypothesized that we should be able to 
inhibit Aβ binding to cells and Aβ toxicity by providing a soluble source of sialic acid in 
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the culture medium, which would compete with the cell membrane for Aβ binding. As a 
control, we examined the effects of sialic acid from 0 to 2 or 5 mM on differentiated SH-
SY5Y or PC12 cell viability.  At these concentration ranges, sialic acid had no effect on 
cell viability (data not shown).  We then examined the ability of free sialic acid to 
attenuate Aβ toxicity in PC12 cells.  As can be seen in Figure 7.2, at the lowest 
concentration of Aβ used, 5 µM, the cell viability increased as a function of sialic acid 
dosage, up to a saturation viability level. This protective effect was a strong function of 
the concentration of Aβ, with little protection offered by the sialic acid for 
concentrations of Aβ equal to or above 10 µM. There are several probable reasons why 
free sialic acid did not protect cells from toxicity at high Aβ levels.  Based on the 
viability data shown in Fig. 7.2, a binding affinity of Aβ for free sialic acid can be 
estimated to be on the order of 10-4 M, while Aβ affinity for gangliosides has been 
estimated to be of the order 10-6 M [231, 239] suggesting that even higher concentrations 
of free sialic acid would be needed to compete with Aβ-ganglioside binding.  Moreover, 
based on stoichiometric arguments, the data indicate that Aβ binds to more than one 
sialic acid molecule.  This interpretation is consistent with findings that Aβ affinity is 
greatest for gangliosides that are clustered in cholesterol rich microdomains [229]. 
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Fig. 7.2.  Attenuation of Aβ induced toxicity by free sialic acid.  5 µM Aβ (♦) shows an 
increase in viability of 30% from control (0 sialic acid) for sialic acid concentrations above 
0.5 mM (Tukey, p < 0.005).  10 µM (S), 15 µM (z), and 20 µM () show no significant 
difference from control. 
 
 
 We next synthesized sialic acid containing dendridic polymers of varying size 
and sialic acid functionality to test if the clustered sialic acid residues presented by these 
polymers would better protect cells from Aβ toxicity than soluble sialic acid.  Others 
have used similar types of sialic acid modified dendridic polymers to prevent viral 
adhesion (infection) both in vitro and in vivo [248-250], suggesting that such a strategy 
might be fruitful in treating disease.  
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Dendrimer toxicity  
 Generation 2.0, 3.0 and 4.0 PAMAM dendrimers were used in our studies.  
Toxicity of dendrimers at concentrations ranging up to either 250 µM, 125 µM and 130 
µM for generation 2.0, 3.0, and 4.0 dendrimers, respectively, were assessed using 
differentiated SH-SY5Y cells.  The LD50 values estimated from the results of these 
experiments are shown in Table 7.1. The intrinsic dendrimer toxicity increased with 
generation number implying that the toxicity of the dendrimer was related to either 
molecular weight of the molecule, the number of terminal amine groups, or both. The 
detrimental influence of dendrimers has been discussed in previous works [248, 251]. 
We also evaluated the toxicity of the sialic acid-conjugated dendrimers (all generations) 
in experiments analogous to those performed with unmodified dendrimers. LD50 values 
for the sialic acid modified dendrimers are also shown in Table 7.1.   
 
Table 7.1.  LD50 values for conjugated and unconjugated dendrimers of different 
generations 
 
 
Generation 
Unconjugated 
Dendrimer (µM) 
 
Conjugated Dendrimer 
(µM) 
 
2.0 50 + 40 84 + 17 
3.0 10 + 7 42 + 14 
4.0 1.7 + 0.2 3.5 + 1.2 
 
All generations show a decline in intrinsic toxicity upon conjugation with 
sialic acid.  All values are found to be statistically different from all other 
values (studentized-t, p < 0.05). 
 
In all cases, sialic acid modification significantly decreased the toxicity or LD50 value of 
the dendrimer. This result is consistent with work by a number of other groups which 
showed that polycation toxicity was a strong function of both mass and charge [251, 
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252] and that increased surface modification of amine terminated dendrimers led to a 
decrease in their toxicity [248].  Together, these results support the idea that the 
dendrimer surface charges is one of the factors attributing to intrinsic toxicity.   
 
Attenuation of toxicity of Aβ by dendrimer-SA complexes 
 In Figure 7.3, we show the effect of unmodified dendrimers and dendrimer-sialic 
acid conjugates on Aβ toxicity in differentiated SH-SY5Y cells.  In all cases, cells were 
treated with 50 µM Aβ.  Increase in cell viability relative to cells just treated with Aβ is 
plotted.  Typical cell viability after 24 hour treatment with 50 µM Aβ as prepared in our 
laboratory is about 60 %. It can be seen that for generation 2.0, the protective effect of 
the dendrimer-sialic acid complex increases with concentration up to around 5.5 µM, 
and then saturates. For generation 3.0, the protective effect increases with dendrimer-
sialic acid complex concentration up to 11 µM and then starts to decrease. For 
generation 4.0, the protective effect increases up to a concentration of about 1.5µM and 
then decreases rapidly. This phenomenon of decreasing protection at the higher 
concentrations of dendrimer, especially for the higher generation dendrimer, may be 
explained by the relatively high intrinsic toxicity of the generation 3.0 and 4.0 
dendrimers. It should be noted that for the unconjugated dendrimers, there is significant 
protection exhibited against Aβ toxicity. However, upon sialic acid-conjugation, the 
protection levels increase by up to 200%.  
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Fig 7.3.  Attenuation of Aβ toxicity by conjugated and unconjugated 
dendritic compounds of different generations.  a) Conjugated (solid line, 
filled) generation 2.0 shows a substantial increase in protection compared 
to unconjugated dendrimer(dashed line, open).  While for generations 3.0 
(b) and 4.0 (c), there is an initial improvement in protection followed by a 
waning at higher concentrations.   
 
 This small protective interaction of the unconjugated dendrimer is not surprising.  
It has been suggested that cell surface binding of Aβ is dictated by electrostatic 
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interactions, and preventing these interactions decreases Aβ toxicity [97].  We suggest 
that both forms of the dendrimer (conjugated and unconjugated) protect cells from Aβ 
toxicity in different ways.  The presence of the primary amines and large positive surface 
charge on the unconjugated dendrimer leads to an electrostatic interaction of the 
dendrimer with the negatively charged cell membrane, preventing the Aβ from binding 
and, therefore, blocking toxicity.  Unfortunately, this dendrimer interaction with the cell 
surface can lead to cell death, as found here and in Fischer et. al. [251].  Conversely, we 
postulate that the conjugated dendrimer prevents the interaction of Aβ with the cell 
surface not by blocking the cell surface, but by sequestering the Aβ.   
 
Efficiences of the different generations of dendrimer-sialic acid complexes 
 Taking into account both the protectiveness and intrinsic toxicity of conjugated 
polymers, we developed an empirical model that correlates the normalized viability 
provided by modified and unmodified dendrimers for Aβ treated cells.  Two constants 
were obtained from fitting the model to the experimental data shown in Figure 7.3, Ki, 
which represents the inhibition by the sialic acid containing dendrimer of Aβ toxicity, 
and kt, which represents the intrinsic toxicity of the dendrimer conjugate. Table 7.2 
shows the constants Ki and kt of this model for the different generations of sialic acid-
conjugated dendrimer.  
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Table 7.2.  Model constants for different generations of sialic acid-conjugated 
dendrimers 
 
Generation 
 
Ki (µM) 
 
kt (µM) 
 
2.0 33.06 + 0.17 0.45 + 0.013 x 10-3 
3.0 14.64 + 0.04 2.89 + 0.008 x 10-6 
4.0 13.36 + 0.20 18.0 + 0.3 x 10-3 
 
The binding constant, Ki, decreases with increasing generation number, 
indicating greater binding affinity for Aβ.  The toxicity constant, kt, increases by 
an order of magnitude with each increase in generation number.  Model fits 
showed R2 values of 0.93, 0.86, and 0.96 for generations 2,3, and 4, respectively.  
All values reported represent a 95% confidence interval.  Statistical differences 
of Ki and kt of different generations are found to be significant (p < 0.0001). 
 
It is clear that the protective property constant Ki decreases with increase in generation 
number, indicating that generation 4.0 is more efficient than generation 3.0, which in 
turn is more efficient than generation 2.0 at protecting cells from Aβ toxicity.   Ki was 
estimated per mole equivalent sialic acid, not per mole dendrimer.  If estimated per mole 
dendrimer, Ki values would vary from approximately 2 µM, 0.5 µM and 0.2 µM for 
generations 2.0, 3.0 and 4.0 sialic acid modified dendrimers, respectively, further 
accentuating the significance of the differences in toxicity attenuation properties of the 
different generation dendrimer constructs.  However, on examination of the kt values, it 
is evident that generation 4.0 is an order of magnitude more toxic than generation 3.0, 
which is another order of magnitude more toxic than generation 2.0. This explains why 
the increase in viability by the generation 2.0 complex saturates, while the increase in 
viability by the generation 3.0 and 4.0 complexes decreases at higher concentrations up 
to the extent that no protection is observed.   
 One plausible reason as to why clusters of sialic acid are more efficient than free 
sialic acid molecules in protecting cells from Aβ induced toxicity is that the clustered 
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sialic acid compounds more closely mimic cell surface gangliosides.  It has been shown 
that Aβ binds with highest affinity to gangliosides that either contain multiple sialic acid 
residues or that are clustered in cholesterol rich membranes [229, 231].  Also, clustering 
sialic acid greatly improves the probability of interaction between clustered sialic acids 
“tethered” to the already bound sialic acid molecule and virial particles [248, 250, 253].  
Similar phenomena probably occur during Aβ sialic acid dendrimer interactions. Finally, 
unlike free sialic acid, clustered sialic acid molecules are more stable and are not 
vulnerable to enzymatic breakdown when exposed to biological fluids [248].   
To date, there have been many attempts at developing either a prevention or cure 
for AD, each involving different stages of pathogenesis. Strategies which alter APP 
processing  and thereby reduce formation of Aβ have had some success in animal 
models at reducing Aβ(1-40) levels, but have not been without some significant 
limitations [253, 254].  Agents which prevent Aβ aggregation and/or reverse fibril 
formation have had success in vitro and have potential as in vivo therapeutics [230, 255, 
256].  Immunotherapies involving clearance of aggregated Aβ showed early promise in 
both animal models and humans, but are currently associated with unacceptable side 
effects [101-103].  However, there is evidence that agents which sequester Aβ in the 
plasma may actually be effective at reducing Aβ levels in the cortex and may have the 
potential of reducing cognitive decline associated with disease [104, 257].  These studies 
suggest that sialic acid based molecules that have a high affinity for Aβ such as the ones 
we describe here may contribute to the array of therapeutic agents being developed for 
treatment of AD.  
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Conclusions 
 It is clear that interactions between Aβ and membrane-bound sialic acid play an 
important role in neurotoxicity, and it is possible that by introducing sialic acid for direct 
competition with the cell surface, the neurotoxic effects of Aβ can be mitigated.  
Moreover, by clustering sialic acid residues, we can more closely mimic cell surfaces to 
create improve competition efficiency.  The results from all three dendrimer generations 
tested support these claims.  The findings encourage further investigation into the 
development of biomimetic compounds for use in prevention of Aβ toxicity.  
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CHAPTER VIII 
 
DEVELOPMENT OF NOVEL SIALIC ACID LABELED DENDRIMERS AS A 
POSSIBLE THERAPEUTIC TOOL FOR THE PREVENTION OF β-AMYLOID 
TOXICITY ASSOCIATED WITH ALZHEIMER’S DISEASE 
 
Introduction 
As previously discussed, Alzheimer’s disease (AD) is the leading cause of 
neurodegeneration in the United States, affecting approximately 4.5 million Americans 
in 2003 [232], with an annual cost of care for these individuals estimated at over $100 
billion [233]. With the cause of the neurotoxicity being linked to to the presence of Aβ 
fibrils [99, 235 - 237], we propose that by targeting these fibrils, we can prevent toxicity 
via sequestering these fibrils.  This technique has been demonstrated by previous work 
[97, 101-104], but little has been done to make these sequestering agents more 
biomimetic.  It is this area we look to explore. 
A variety of evidence indicates that Aβ may bind to cells via an interaction with 
surface glycolipids or glycoproteins with increased binding occurring in the presence of 
gangliosides or other sialic acid containing molecules that cluster the sialic acids [100, 
217, 229, 231, 238-241].  Based on these data, we hypothesized that membrane mimics 
could be synthesized which would reproduce the clustered sialic acid structure of the cell 
surface, and therefore compete with the cell surface for Aβ binding.  It is this work that 
we will discuss. 
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Materials and methods 
Materials 
 All materials purchased from Sigma Aldrich Corporation (St. Louis, MO). 
 
Dendrimer labeling - acetylation of sialic acid (compound 1) 
 The acetyl protection was performed by first dissolving 250 mg of NANA in 10 
mL of pyridine.  To this solution was added 537 mg (497 uL) of acetic anhydride and 37 
mg of 4-(dimethylamino)pyridine (DMAP).  The solution was reacted at room 
temperature for 3 hours.  After 3 hours, a 1 mL solution of hydrazine acetate in dimethyl 
formamide (DMF) was added to the pyridine solution.  The mixture was reacted at 55oC 
for 15 min.  A 1 mL volume of trichloroacetonitrile and 45.3 uL of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) were then added, and the system was reacted at 
0oC for 1.5 hours.  The final solution was stored at -80oC until used.  This procedure was 
adapted from Ren et al. [258]. 
 
Dendrimer labeling – production of 2-(2-isothiocyanatoethoxy ethanol) (compound 2) 
 A solution containing 700 uL of  2-(2-aminoethoxy)ethanol and 2 mL of 
triethylamine in 10 mL of chloroform was added slowly over the course of an hour to a 
stirred solution containing 540 uL of thiophosgene in 40 mL of chloroform.  The solvent 
was removed in vacuo.  The resulting residue was dissolved in 10 mL of deionized 
water.  A two-step extraction was performed using two 10 mL volumes of 
dichloromethane.  The organic phases from the extraction were combined and washed 
 138
twice with deionized water (2 x 10 mL).  The organic layer was then dried over 
magnesium sulfate and filtered.  The solvent was removed in vacuo.  The resulting 
yellowish oil was stored at -80oC until used.  This procedure was adapted from Woller et 
al. [259, 260]. 
 
Dendrimer labeling – attachment of compound 2 to dendrimer (compound 3) 
 A 100 uL solution of generation 4.0 polyamidoamine (PAMAM) (0.57 µmol of 
dendrimer)  was evaporated under reduced pressure.  The resulting residue was dissolved 
in 5 mL of dimethyl sulfoxide (DMSO).  A ten-fold molar excess of compound 2 was 
added to the DMSO mixture (this excess is based on the number of terminal amines 
available on the dendrimer and not the amount of dendrimer).  The solution was reacted 
at room temperature for 8 hours.  The solvent was removed in vacuo.  This procedure 
was adapted from Woller et al. [259, 260]. 
 
Dendrimer labeling – attachment of sialic acid (compound 4) 
 The residue of compound 3 was dissolved in 20 mL of dichloromethane with 10 
mg of 4Å molecular sieves under nitrogen.  To the solution, 50 µmoles (1 mL) of 
compound 1 and 200uL boron trifluoride-diethyl etherate was added slowly.  The 
solution was reacted at room temperature for 7 hours.  Sodium bicarbonate (100 mg) was 
added to the solution, and the solution was filtered over celite.  The solvent was removed 
in vacuo.  The resulting compound was stored at -80oC until used.  This procedure was 
adapted from Woller et al. [259, 260]. 
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Dendrimer labeling – deprotection of sialic acid 
 Compound 4 was dissolved in 20 mL of a methanol/deionized water mixture 
(1:1).  Methanolic base (1 M, 180 uL) was added, and the solution was mixed overnight 
until all solid was dissolved.  The solution was neutralized with Amberlite IR-120 and 
filtered using a glass filter.  The solvent was removed in vacuo.  The resulting residue 
was dissolved in deionized water, and purified using 10 kDa centrifuge filter units.  The 
resulting solution was stored at 4oC until used.  This procedure was adapted from Woller 
et al. [259, 260]. 
 
Determination of sialic acid labeling 
 The extent of sialic acid labeling was determined using the procedure described 
by Warren [261] with minor modifications.  As opposed to stopping the reaction, we just 
cooled the samples under tap water, centrifuged, and read.  This step was performed 
after FTIR verification of sialic acid attachment to the dendrimer. 
 
Results and discussion 
FTIR analysis of dendrimer-sialic acid compound 
 Using standard FTIR techniques, an evaporated sample of the dendrimer-sialic 
acid compound was analyzed for characteristic peaks.  The results of this analysis can be 
found in Figure 8.1 
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Fig 8.1. FTIR analysis of sialic acid-labeled dendrimer.  The solid line represents generation 4.0 dendrimer.  The 
dashed line represent the sialic acid-labeled dendrimer.  The peaks of interest are as follows:  1562 & 3085 – loss of 
primary amines in the dendrimer; 1700 – presence of carboxylic acids from the sialic acid; 1112, 1175 & 1368 – 
formation of  thiourea structure; 1032 – alicyclic alcohols from sialic acid. 
 
 
From the FTIR analysis, it is apparent by the presence of certain characteristic 
structures (thiourea, carboxylic acids, and alicyclic alcohols) and the loss of other peaks 
(amine structure loss) that the chemistry was successful.  Determination of sialic acid 
labeling via the Warren assay indicates that we have complete labeling.  This is 
commensurate with what has been found by others [259, 260]. 
Initial studies with the new sialic acid-labeled dendrimer indicate that is has 
higher protective properties than those produced through EDC chemistry (Chapter VII).  
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Furthermore, the protection curves indicate that the binding is via a different mechanism.  
However, there is currently not enough data to make any definitive statements. 
 
Conclusions 
 If the preliminary data holds up, then this is an indication that both the labeling 
amount and sialic acid confirmation influence the binding properties of these dendrimers 
to Aβ.  Based on the work presented in Chapter VII, it would be useful to analyze other 
generations of dendrimers for similar characteristics and less intrinsic toxicity.  
Eventually, it would be necessary to address the ability of the compound to pass the 
blood-brain barrier, but this is a distant concern. 
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CHAPTER IX 
 
CONCLUSIONS 
 
 This project has tied together many different aspects important to sensor design.  
First, we utilized standard kinetic and spectroscopic principles to develop models that 
could be use for general sensor design.  We then successfully applied these principles 
and results of the modeling toward several different biomedically relevant sensing 
platforms and targets.  We have proven the flexibility and robustness of the systems we 
have developed and laid the ground work for substantial future work in the area. 
 We were successful in using a commercially available antibody for the 
development of a prion sensor.  Through experimental and theoretical analysis, we 
determined that the detection limits for the prion sensor, or any competitive sensor, are 
always dictated by the equilibrium bind coefficient.  Regardless of how the system 
model was modified, these limitations always applied.  We realized that to achieve lower 
detection limits, we would have to develop a direct sensing method. 
Using what we learned from the prion sensor, we worked at developing a direct 
sensor for Aβ using SERS as the detection method.  With the strong distance 
dependence of SERS, we had to develop a recognition molecule that was smaller than an 
antibody, but still maintained high specificity.  We accomplished this by creating sialic 
acid-labeled materials.  These materials included sialic acid-labeled monolayers, 
ganglioside and artificial ganglioside monolayers, and sialic acid-labeled dendrimers.  
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The latter structures were developed to more closely mimic biological structures.  We 
found that as the number of sialic acids increased, so did the binding affinity of Aβ.  We 
demonstrated the feasibility of using these materials in a sensing platform.  We also 
tested the use of some of these materials in vitro toxicity studies to examine is such 
materials could protect cells from Aβ toxicity.  While the sialic acid labeled dendrimers 
could prevent Aβ neurotoxicity at low concentrations, there use was limited by their 
toxicity at high concentrations. 
With success from the first attempts with sialic acid attachment, we investigated 
the issue of sialic acid conformation (to more closely mimic biological arrangement).  
Using an adaptation of techniques developed by synthetic chemists, we successfully 
altered the conformation of sialic acid attachment to more closely mimic that found in 
gangliosides and other biological molecules.  Furthermore, this altered attachment 
showed substantially greater protective properties than the simpler attachment used 
previously to attenuate Aβ neurotoxicity.   These materials may be useful as therapeutics 
for Alzheimer’s disease treatment.  
I feel this project demonstrates a firm understanding of material design, analysis 
and application techniques.  It incorporates a broad base of knowledge form several 
disciplines (biomedical engineering, biochemical engineering, material science, food 
engineering, and optical design).  It is this cross-disciplinary work that lends itself to 
successful expansion of the field of biosensors. 
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Future Work 
 As with any project, there is always more you wished you could have done, but 
time is always a limitation.  I feel that all the work I have done has laid the groundwork 
for many advances. 
 For the prion sensor, the background and design principles have been 
investigated..  A working platform has been developed, but there is substantial room for 
optimization.  The sensor, as it currently stands, is not selective for infectious prion only.  
By altering the recognition unit to an antibody that targets only infectious prion, this can 
be addressed.  Furthermore, by altering the fluorophore that is used, we could improve 
the signaling capability of the sensor by selecting a fluorophore appropriate for the 
system we are working with (high quantum efficiency for quenching, low quantum 
efficiency for enhancement).  Finally, we need to address the response of the system 
with actually sample.  This may require some adjustments for sample pretreatment, 
fluorophore detection, and antibody selection, just to name a few.  I intend to pursue this 
in my future works. 
 With the OPH sensor, we have been more successful in understanding the 
shortcomings of the systems than in determining its strengths.  However, this leaves the 
project wide open for possible advancements.  Based on the modeling the results, the 
system shows a lot of promise, but due to budgetary constraints, time constraints, and 
experimental complications, this promise has not come to fruition.  I hope to do further 
investigations in enzymatic sensors in the future. 
 145
 Finally, the work in detection and treatment of Alzheimer’s disease (via Aβ 
interaction) has shown tremendous potential.  All indications are that sialic acid 
interaction with Aβ is highly successful and well thought out.  With trends in our data 
indicating that increased clustering of sialic acid being more effective, we definitely 
appear to be heading in the right direction.  However, I propose that there are other 
molecules outside gangliosides that may be influencing the binding of Aβ (neuronal cell 
adhesion molecule (NCAM)). 
Additionally, this project has addressed the use of SERS as a sensing platform in 
a way the previously had not been attempted.  In combination with our foray into 
synthetic chemistry, I feel this project significantly demonstrates the importance of 
looking beyond your current boundaries and knowledge.  With the success of initial 
experiments in this project, I believe that this system could have major impacts on both 
diagnosis and treatment of Alzheimer’s disease. 
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